Document:

Lease with Sandy Park II L.L.C.

 Exhibit 10.1 
 LEASE 
 by and between 

SANDY PARK II L.L.C., 
 a Utah Limited Liability Company, 
 as Landlord 

and 

LIFEVANTAGE CORPORATION, 
 a Colorado corporation 
 as Tenant 

for 
 Third and
Fourth Floors 
 SANDY PARK OFFICE COMPLEX 
 9800 SOUTH MONROE STREET 
 SANDY, UTAH 

 SANDY PARK OFFICE COMPLEX—9800 SOUTH MONROE STREET—SANDY, UTAH 

TABLE OF CONTENTS 
  

					
	 ARTICLE I. BASIC LEASE PROVISIONS; ENUMERATION OF EXHIBITS
	  	 	3	  
	 SECTION 1.01 BASIC LEASE PROVISIONS
	  	 	3	  
	 SECTION 1.02 SIGNIFICANCE OF A BASIC LEASE PROVISION
	  	 	6	  
	 SECTION 1.03 ENUMERATION OF EXHIBITS
	  	 	6	  
	 ARTICLE II. GRANT AND LEASED PREMISES
	  	 	6	  
	 SECTION 2.01 LEASED PREMISES
	  	 	6	  
	 ARTICLE III. RENT
	  	 	6	  
	 SECTION 3.01 BASE MONTHLY RENT
	  	 	6	  
	 SECTION 3.02 ESCALATION
	  	 	7	  
	 SECTION 3.03 TENANT’S SHARE OF OPERATING EXPENSES
	  	 	7	  
	 SECTION 3.04 TAXES
	  	 	9	  
	 SECTION 3.05 PAYMENTS
	  	 	9	  
	 ARTICLE IV. RENTAL TERM, COMMENCEMENT DATE & PRELIMINARY TERM
	  	 	9	  
	 SECTION 4.01 RENTAL TERM
	  	 	9	  
	 SECTION 4.02 RENTAL COMMENCEMENT DATE
	  	 	9	  
	 SECTION 4.03 PRELIMINARY TERM
	  	 	9	  
	 ARTICLE V. CONSTRUCTION OF LEASED PREMISES
	  	 	9	  
	 SECTION 5.01 CONSTRUCTION BY LANDLORD
	  	 	9	  
	 SECTION 5.02 CHANGES AND ADDITIONS BY LANDLORD
	  	 	10	  
	 SECTION 5.03 DELIVERY OF POSSESSION
	  	 	10	  
	 ARTICLE VI. TENANT’S WORK & LANDLORD’S CONTRIBUTION
	  	 	10	  
	 SECTION 6.02
	  	 	10	  
	 ARTICLE VII. USE
	  	 	10	  
	 SECTION 7.01 USE OF LEASED PREMISES
	  	 	10	  
	 SECTION 7.02 HAZARDOUS SUBSTANCES
	  	 	11	  
	 ARTICLE VIII. OPERATION AND MAINTENANCE OF COMMON AREAS.
	  	 	11	  
	 SECTION 8.01 CONSTRUCTION AND CONTROL OF COMMON AREAS
	  	 	11	  
	 SECTION 8.02 LICENSE
	  	 	12	  
	 SECTION 8.03 AUDIT
	  	 	12	  
	 ARTICLE IX. ALTERATIONS, SIGNS, LOCKS & KEYS
	  	 	12	  
	 SECTION 9.01 ALTERATIONS
	  	 	12	  
	 SECTION 9.02 SIGNS
	  	 	13	  
	 SECTION 9.03 LOCKS AND KEYS
	  	 	13	  
	 ARTICLE X. MAINTENANCE AND REPAIRS; ALTERATIONS; ACCESS
	  	 	13	  
	 SECTION 10.01 LANDLORD’S OBLIGATION FOR MAINTENANCE
	  	 	13	  
	 SECTION 10.02 TENANT’S OBLIGATION FOR MAINTENANCE
	  	 	13	  
	 SECTION 10.03 SURRENDER AND RIGHTS UPON TERMINATION
	  	 	14	  
	 ARTICLE XI. INSURANCE AND INDEMNITY
	  	 	14	  
	 SECTION 11.01 LIABILITY INSURANCE AND INDEMNITY
	  	 	14	  
	 SECTION 11.02 FIRE AND CASUALTY INSURANCE
	  	 	15	  
	 SECTION 11.03 WAIVER OF SUBROGATION
	  	 	15	  
	 ARTICLE XII UTILITY CHARGES
	  	 	15	  
	 SECTION 12.01 OBLIGATION OF LANDLORD
	  	 	15	  
	 SECTION 12.02 OBLIGATIONS OF TENANT
	  	 	16	  
	 SECTION 12.03. EXTRA HOURS CHARGES
	  	 	16	  
	 SECTION 12.04. LIMITATIONS ON LANDLORDS LIABILITY
	  	 	16	  
	 ARTICLE XIII. OFF-SET STATEMENT, ATTORNMENT AND SUBORDINATION
	  	 	17	  
	 SECTION 13.01 OFF-SET STATEMENT
	  	 	17	  
	 SECTION 13.02 ATTORNMENT
	  	 	17	  
	 SECTION 13.03 SUBORDINATION
	  	 	17	  
	 SECTION 13.04 MORTGAGEE SUBORDINATION
	  	 	17	  
	 SECTION 13.05 REMEDIES
	  	 	17	  
	 ARTICLE XIV. ASSIGNMENT
	  	 	17	  
	 SECTION 14.01 ASSIGNMENT
	  	 	17	  
	 ARTICLE XV. WASTE OR NUISANCE
	  	 	18	  
	 SECTION 15.01 WASTE OR NUISANCE
	  	 	18	  
	 ARTICLE XVI. NOTICES
	  	 	18	  
	 SECTION 16.01 NOTICES
	  	 	18	  
	 ARTICLE XVII. DESTRUCTION OF THE LEASED PREMISES
	  	 	18	  
	 SECTION 17.01 DESTRUCTION
	  	 	18	  

  
 i 

 SANDY PARK OFFICE COMPLEX—9800 SOUTH MONROE STREET—SANDY, UTAH 

TABLE OF CONTENTS 
  

					
	 ARTICLE XVIII. CONDEMNATION
	  	 	19	  
	 SECTION 18.01 CONDEMNATION
	  	 	19	  
	 ARTICLE XIX. DEFAULT OF TENANT
	  	 	19	  
	 SECTION 19.01 DEFAULT—RIGHT TO RE-ENTER
	  	 	19	  
	 SECTION 19.02 DEFAULT—RIGHT TO RE-LET
	  	 	19	  
	 SECTION 19.03 LEGAL EXPENSES
	  	 	20	  
	 ARTICLE XX. BANKRUPTCY, INSOLVENCY OR RECEIVERSHIP
	  	 	20	  
	 SECTION 20.01 ACT OF INSOLVENCY, GUARDIANSHIP, ETC
	  	 	20	  
	 ARTICLE XXI. LANDLORD ACCESS
	  	 	20	  
	 SECTION 21.01 LANDLORD ACCESS
	  	 	20	  
	 ARTICLE XXII LANDLORD’S LIEN
	  	 	20	  
	 SECTION 22.01 LANDLORD’S LIEN
	  	 	20	  
	 ARTICLE XXIII. HOLDING OVER
	  	 	21	  
	 SECTION 23.01 HOLDING OVER
	  	 	21	  
	 SECTION 23.02 SUCCESSORS
	  	 	21	  
	 ARTICLE XXIV. RULES AND REGULATIONS
	  	 	21	  
	 SECTION 24.01 RULES AND REGULATIONS
	  	 	21	  
	 ARTICLE XXV. QUIET ENJOYMENT
	  	 	21	  
	 SECTION 25.01 QUIET ENJOYMENT
	  	 	21	  
	 ARTICLE XXVI. SECURITY DEPOSIT
	  	 	21	  
	 SECTION 26.01 SECURITY DEPOSIT
	  	 	21	  
	 ARTICLE XXVII. MISCELLANEOUS PROVISIONS
	  	 	22	  
	 SECTION 27.01 WAIVER
	  	 	22	  
	 SECTION 27.02 ENTIRE LEASE AGREEMENT
	  	 	22	  
	 SECTION 27.03 FORCE MAJEURE
	  	 	22	  
	 SECTION 27.04 LOSS AND DAMAGE
	  	 	22	  
	 SECTION 27.05 ACCORD AND SATISFACTION
	  	 	22	  
	 SECTION 27.06 NO OPTION
	  	 	22	  
	 SECTION 27.07 ANTI-DISCRIMINATION
	  	 	22	  
	 SECTION 27.08 SEVERABILITY
	  	 	22	  
	 SECTION 27.09 OTHER MISCELLANEOUS PROVISIONS
	  	 	23	  
	 SECTION 27.10 REPRESENTATION REGARDING AUTHORITY
	  	 	23	  
	 SECTION 27.11 DISCLOSURE OF PARTIES
	  	 	23	  
	 SECTION 27.12 TENANT CERTIFICATION
	  	 	23	  
	 SIGNATURES
	  	 	23	  
	 ACKNOWLEDGEMENT OF LANDLORD
	  	 	24	  
	 ACKNOWLEDGMENT OF TENANT
	  	 	24	  

  
 ii 

 LEASE 
 ARTICLE I. BASIC LEASE PROVISIONS; ENUMERATION OF EXHIBITS 
 SECTION
1.01 BASIC LEASE PROVISIONS 
  

	(A)	DATE: September 20, 2012. 

  

	(B)	LANDLORD: SANDY PARK II L.L.C., a Utah limited liability company. 

  

	(C)	ADDRESS OF LANDLORD FOR NOTICES (Section 16.01): 2733 East Parleys Way, Suite 300, Salt Lake City, UT 84109. 

 

	(D)	TENANT: LIFEVANTAGE CORPORATION, a Colorado corporation (FIN: 90-0224471). 

 

	(E)	ADDRESS OF TENANT FOR NOTICES (Section 16.01): 9815 South Monroe St., Sandy Utah 84070, Attn: Legal Department, Phone: (801) 432-5000.

  

	(F)	PERMITTED USES (Section 7.01): General office including business administration, sales, training and marketing of products. 

 

	(G)	TENANT’S TRADE NAME (Exhibit “E”—Sign Criteria): LifeVantage. 

 

	(H)	PROJECT (Section 2.01): Sandy Park Office Complex consisting of one building situated at 9800 South Monroe Street in Sandy City, County of Salt Lake, State of
Utah. The gross rentable square feet for the building is 84,490. 

  

	(I)	LEASED PREMISES (Section 2.01): That portion of the building at the approximate location outlined on Exhibit “A” and “A-1”, consisting of
floors three (3) and four (4) with a gross rentable area of approximately 44,353 square feet. Approximately 10.19% of such area is Tenant’s proportionate share of common area hallway’s, restrooms, etc. of the Building.

  

	(J)	DELIVERY OF POSSESSION (Section 5.03): Preliminary Term begins on Delivery of Possession (Section 4.03), which is estimated to be September 1, 2013.

  

	(K)	RENTAL TERM, COMMENCEMENT AND EXPIRATION DATE (Sections 4.01 & 4.02): The Rental Term shall commence on the Delivery of Possession, and shall be for a
period of ten (10) full Lease Years which is estimated to be August 31, 2023. 

  

	(L)	BASE MONTHLY RENT (Section 3.01): Eighty Six Thousand Eight Hundred Fifty-Eight and 23/100 Dollars ($86,858.23). 

 

	(M)	ESCALATIONS IN BASE MONTHLY RENT (Section 3.02): 

  

					
	 Escalation Commencement
	  	Monthly Payment	 
	 Commencing the 1st day of the 13th month
 after the Rental Commencement Date
	  	$	90,554.33	  
	 Commencing the 1st day of the 25th month
 after the Rental Commencement Date
	  	$	94,250.42	  
	 Commencing the 1st day of the 37th month
 after the Rental Commencement Date
	  	$	97,946.52	  
	 Commencing the 1st day of the 49th month
 after the Rental Commencement Date
	  	$	101,642.61	  
	 Commencing the 1st day of the 61st month
 after the Rental Commencement Date
	  	$	105,338.71	  
	 Commencing the 1st day of the 73rd month
 after the Rental Commencement Date
	  	$	109,034.86	  

  
 3 

					
	 Commencing the 1st day of the 85th month
 after the Rental Commencement Date
	  	$	112,730.96	  
	 Commencing the 1st day of the 97th month
 after the Rental Commencement Date
	  	$	116,426.99	  
	 Commencing the 1st day of the 109th month

after the Rental Commencement Date
	  	$	120,123.09	  

  

	(N)	LANDLORD’S SHARE OF OPERATING EXPENSES (Section 3.03): Landlord shall pay all Operating Expenses for the first twelve (12) months of the Rental Term
and an amount equal to the Operating Expenses for the calendar year 2014 (the “Base Year”) each year thereafter. 

  

	(O)	TENANT’S PRO RATA SHARE OF OPERATING EXPENSES (Section 3.03): Fifty-Two and a Half percent (52.50%) of all Operating Expenses as defined in Section
3.03 in excess of Landlord’s Share of Operating Expenses. 

  

	(P)	RESPONSIBILITY FOR UTILITIES AND SERVICES: Subject to the provisions of Section 3.03, this Lease provides that the utilities and services shall be paid by the
party shown below: 

  

							
	 Heat:
	  	Landlord	  	Real Property Taxes:	  	Landlord
	Water:	  	Landlord	  	Personal Property Taxes:	  	Tenant
	Telephone:	  	Tenant	  	Janitorial:	  	Tenant
	Electricity:	  	Landlord	  	Building Casualty Insurance:	  	Landlord
	Common Area Maintenance:	  	Landlord	  	Personal Property Insurance:	  	Tenant
	Liability Insurance-Premises:	  	Tenant	  	Liability Ins.-Common Area:	  	Landlord

 Landlord shall arrange for utility services for Leased Premises except that telephone services shall
be contracted for directly by Tenant. Landlord may separately sub-meter or monitor utilities to the extent Landlord may determine. 
  

	(Q)	EXCESS HOUR UTILITY CHARGES AND HOURS OF OPERATION (Section 12.03): Standard operating hours for the Building shall be 7:00 a.m. to 6:30 p.m. Monday through
Friday and 8:00 a.m. to 12:00 Noon on Saturday, excluding federally recognized holidays on which banks in the state are required to be closed. To the extent Tenant requires utilities, lighting or electricity to be provided for the Building during
any time in excess of those specified above, Tenant shall pay an extra hourly utility charge of twenty-five cents ($0.25) per hour per one thousand (1,000) square feet for lighting and electricity and five dollars ($5.00) per hour per one
thousand (1,000) square feet for mechanical/HVAC system for each full or partial hour during which Tenant operates. 

  

	(R)	TENANT/LANDLORD’S WORK (Exhibit “D”): Landlord shall deliver the Leased Premises in turnkey condition to Tenant in accordance with Exhibit
“D” with Landlord contributing a maximum of One Million Three Hundred Eighty-Six Thousand Seven Hundred and 00/100 Dollars ($1,386,700.00) (“Landlord’s Contribution”) and Tenant shall pay all costs in excess of
Landlord’s Contribution within thirty (30) days of invoice from Landlord. 

  

	(S)	STRUCTURED PARKING (Section 2.01): Tenant shall be entitled to the use of five (5) covered parking spaces per one thousand (1,000) square feet of gross
rentable area. Notwithstanding anything in this Lease to the contrary, Tenant’s parking shall not be materially changed without Tenant’s prior written consent. 

 

	(T)	PREPAID RENT: Eighty-Six Thousand Eight Hundred Fifty-Eight and 23/100 Dollars ($86,858.23) paid upon execution of this Lease to be applied to the first
installment of Base Monthly Rent due hereunder. 

  

	(U)	SECURITY DEPOSIT (Section 26.01): One Hundred Ten Thousand and 00/100 Dollars ($110,000.00). 

 

	(V)	Intentionally Omitted. 

  

	(W)	Intentionally Omitted. 

  
 4 

	(X)	 RIGHT OF FIRST OFFER: Landlord hereby grants to Tenant a right to lease the Qualified Space (as defined below) on and subject to the terms and
conditions set forth in this Section. As used herein, “Qualified Space” means any vacant on the floor directly below the Leased Premises (2nd Floor) space of the Building that becomes available during the term of this Lease, including without limitation, any
extensions or renewals thereof. Provided that Tenant is not in default of this Lease, Landlord shall offer to lease the Qualified Space to Tenant on terms and conditions that are acceptable to Landlord (“Offer Proposal”). Tenant shall
either accept or reject the Offer Proposal in writing to Landlord within ten (10) days of receipt of the Offer Proposal (or be deemed to reject the Offer Proposal). If Tenant does not accept such Offer Proposal, or is deemed to reject the Offer
Proposal, Landlord is permitted for a period of one (1) year following the date of such rejection (or deemed rejection) to enter into a third party lease (“Third Party Lease”) for such Qualified Space on terms not less favorable to
Landlord than those contained in the Offer Proposal. If Landlord fails to enter into a third party lease within one (1) year following the date of Tenant’s rejection of the Offer Proposal, Landlord shall reoffer to Tenant the right to
lease the Qualified Space according to the terms above. In such event, Tenant will be deemed to have waived its right to enter into a lease for the Qualified Space. The rights set forth in this Section 1.01(X) are personal to the party executing
this Lease and are not assignable or transferable. Upon a permitted assignment or subletting of this Lease the rights under this Section 1.01(X) shall expire and be of no further force and effect. Tenant’s rights hereunder are conditioned upon
and subject to Tenant’s not being in default beyond any applicable cure period during the time the Tenant accepts such Offer Proposal. 

  

	(Y)	SIGNAGE (Exhibit “E”): Tenant shall have the right to building crown signage on the I-15 facing of the Building. Further, Tenant shall have the right
to suite and monument signage. Costs for Building crown signage will be paid by Tenant or, in Tenant’s discretion, paid out of Landlord’s Contribution. Suite and monument signage will be provided by Landlord as part of Landlord’s
Work. All signage will be designed, constructed, and installed in accordance with building standards in Exhibit “E”. 

  

	(Z)	 TERMINATION RIGHT: Provided the Tenant is not in default in its performance of its obligations under this Lease, Tenant shall have a one-time
right to terminate this Lease at the end of the eighty-fourth (84th) month of the Rental Term by providing one hundred twenty (120) days prior written notice of its exercise of its right to do so. This provision shall only apply during the initial Rental Term
and shall not be applicable to any Extension Term. 

 [Remainder of Page Intentionally Left Blank]

  
 5 

 SECTION 1.02 SIGNIFICANCE OF A BASIC LEASE PROVISION. The foregoing provisions of
Section 1.01 summarize for convenience only certain fundamental terms of this Lease delineated more fully in the Articles and Sections referenced therein. In the event of a conflict between the provisions of Section 1.01 and the balance of this
Lease, the latter shall control. 
 SECTION 1.03 ENUMERATION OF EXHIBITS. The exhibits enumerated in this Section and
attached to this Lease are incorporated in the Lease by this reference and are to be construed as a part of the Lease. 
 EXHIBIT
“A”—SITE PLAN 
 EXHIBIT “A-1”—LEASE PLAN 
 EXHIBIT “B”—LEGAL DESCRIPTION(S) 
 EXHIBIT “C”—TENANT/LANDLORD’S
WORK 
 EXHIBIT “D”—TENANT’S WORK 
 EXHIBIT “E”—SIGN CRITERIA 
 ARTICLE II. GRANT AND LEASED PREMISES

 SECTION 2.01 LEASED PREMISES. In consideration for the rent to be paid and covenants to be performed by Tenant,
Landlord hereby leases to Tenant, and Tenant leases from Landlord for the Rental Term and upon the terms and conditions herein set forth, the premises described in Section 1.01(I) (hereinafter referred to as the “Leased Premises”), located
in an office building development referred to in Section 1.01(H) (hereinafter referred to as the “Building”). The legal description for the property on which the Building is located is attached hereto as Exhibit “B”. Gross
rentable area measurements herein specified are from the exterior of the perimeter walls of the building to the center of the interior walls. 
 The exterior walls and roof of the Leased Premises and the areas beneath said Leased Premises are not demised hereunder and the use thereof together with the right to install, maintain, use, repair, and
replace pipes, ducts, conduits, and wires leading through the Leased Premises in locations which will not materially interfere with Tenant’s use thereof and serving other parts of the building or buildings are hereby reserved to Landlord.
Landlord reserves (a) such access rights through the Leased Premises as may be reasonably necessary to enable access by Landlord to the balance of the building and reserved areas and elements as set forth above; and (b) the right to
install or maintain meters on the Leased Premises to monitor use of utilities. In exercising such rights, Landlord will use reasonable efforts so as to not commit waste upon the Leased Premises and as far as practicable to minimize annoyance,
interference or damage to Tenant when making modifications, additions or repairs. 
 Subject to the provisions of Article VIII
and Section 27.11, Tenant and its customers, agents and invitees have the right to the non-exclusive use, in common with others of such unreserved automobile parking spaces, driveways, footways, and other facilities designated for common use within
the Building, except that with respect to non-exclusive areas, Tenant shall cause its employees to park their cars only in areas specifically designated from time to time by Landlord for that purpose and shall actively police employees to keep them
from parking in “visitor” or other restricted parking areas. Tenant shall be entitled to the use of covered parking spaces in accordance with the provisions of Section 1.01(S). 

ARTICLE III. RENT 
 SECTION 3.01 BASE MONTHLY RENT. Tenant agrees to pay to Landlord the Base Monthly Rent set forth in Section 1.01(L) at such place as Landlord may designate, without prior demand therefor, without
offset or deduction and in advance on or before the first day of each calendar month during the Rental Term, commencing on the Rental Commencement Date. In the event the Rental Commencement Date occurs on a day other than the first day of a calendar
month, then the Base Monthly Rent to be paid on the Rental Commencement Date shall include both the Base Monthly Rent for the first full calendar month occurring after the Rental Commencement Date, plus the Base Monthly Rent for the initial
fractional calendar month prorated on a per-diem basis (based upon a thirty (30) day month). 

  
 6 

 SECTION 3.02 ESCALATION. As set forth in Section 1.01(M). 

SECTION 3.03 TENANT’S SHARE OF OPERATING EXPENSES. (a) Fifty (50%) of all Operating Expenses as defined in Section
3.03 in excess of Landlord’s Share of Operating Expenses set forth in Section 1.01 (N). 
 (b) Landlord
shall bill Tenant for Tenant’s Share, if any, at the end of the second Lease Year of the Rental Term. Beginning with the third Lease Year and continuing thereafter, Landlord shall reasonably estimate Tenant’s Share of Operating Expenses
for the next twelve (12) months and one-twelfth (1/12th) of the estimated Tenant’s Share shall be added to the Base Monthly Rent as determined in Sections 3.01 and 3.02 for the next full twelve (12) calendar months of the Rental
Term and shall be paid as set forth in Section 3.05. 
 (c) To the extent that Tenant’s Share of Operating
Expenses is less or greater than the estimated amount paid by Tenant during Lease Year, Tenant shall be entitled to a reimbursement or shall pay the deficiency as the case may be. Landlord shall determine the actual Operating Expenses within
forty-five (45) days after the end of the Lease Year and shall deliver a computation of such Operating Expenses in reasonable detail to Tenant together with an invoice for Tenant’s share or notice of credit for reimbursement thereof.
Tenant agrees to pay the amount of said invoice within ten (10) days after invoice therefor. 
 (d)
“Operating Expenses” shall mean all reasonable actual costs and expense incurred by Landlord in connection with the ownership, operation, management and maintenance of the Building and Property and related improvements located thereon (the
“Improvements”, including, but not limited to, all reasonable expenses incurred by Landlord as a result of Landlord’s compliance with any and all of its obligations under this Lease (or under similar leases with other tenants). In
explanation of the foregoing, and not in limitation thereof, Operating Expenses shall include: utilities, repair and maintenance of the Leased Premises, including HVAC, electrical, plumbing, sprinkler and other building system maintenance,
(excluding roof and structural repair), all real and personal property taxes and assessments (whether general or special, known or unknown, foreseen or unforeseen) and any tax or assessment levied or charged in lieu thereof, whether assessed against
Landlord and/or Tenant and whether collected from Landlord and/or Tenant; snow removal, trash removal, common area utilities, cost of equipment or devices used to conserve or monitor energy consumption, supplies, insurance, license, permit and
inspection fees, building management fees, cost of services of independent contractors, cost of services of independent contractors, cost of compensation (including employment taxes and fringe benefits) of all persons who perform regular and
recurring duties connected with day-to-day operation, maintenance, repair, and replacement of the Building, its equipment and the adjacent common areas (including, but not limited to janitorial, gardening, landscaping, security, parking, elevator,
painting, plumbing, electrical, mechanical, carpentry, window washing, performing services not uniformly available to or performed for substantially all Building tenants; and rental expense or a reasonable allowance for depreciation of personal
property used in the maintenance, operation and repair of the Building. For purposes hereof, building management fees shall be 4% of the Base Monthly Rentals due and payable. 

(e) The foregoing notwithstanding, Operating Expenses shall not include: 

 

	 	1.	Costs borne directly by Tenant such as janitorial, liability insurance of Tenant and personal casualty insurance; 

 

	 	2.	Cost of decorating, redecorating, or special cleaning or other services not provided on a regular basis to tenants on the Building, unless such decorations or special
cleaning are typical and customary of first class office buildings in the market; 

  

	 	3.	Wages, salaries, fees, and fringe benefits paid to administrative or executive personnel or officers or partners of Landlord unless employed to perform ordinary and
reasonable services at competitive rates as Independent contractors; 

  
 7 

	 	4.	Any charge for depreciation of Building or Building equipment (except improvements made to effect savings as provided above) and any interest or other financing charge;
and except that new or replacement of maintenance equipment, if any, purchased may be depreciated over its useful life and such depreciation charged as an Operating Expense; 

 

	 	5.	Any charge for Landlord’s net income taxes, excess profit taxes, or similar taxes on Landlord’s business excluding any rent tax or any tax measured by
Landlord’s gross receipts from the Building, which shall be deemed an Operating Expense; 

  

	 	6.	All costs relating to activities for the solicitation and execution of leases of space in the building, including, but not limited to, commissions, tenant improvements,
legal fees and marketing expenses; 

  

	 	7.	All costs for which Tenant or any other tenant in the Building directly reimburses Landlord; 

 

	 	8.	The cost of any repair made by Landlord because of the total or partial destruction of the Building or the condemnation of a portion of the Building;

  

	 	9.	The cost of any items for which Landlord is reimbursed by insurance or otherwise compensated by parties other than tenants of the Building; 

 

	 	10.	The cost of any additions or capital improvements to the building subsequent to the date of original construction except as to effect labor savings as provided above;

  

	 	11.	Any Operating Expense representing an amount paid to a related corporation, entity, or person which is in excess of the amount, which would be paid on a competitive
basis for similar services done by unrelated parties of equal qualification; 

  

	 	12.	The cost of alterations of space in the Building leased to other tenants; 

  

	 	13.	The cost of overtime or other expense to Landlord in curing its defaults or performing work expressly provided in this Lease to be borne at Landlord’s expense;

  

	 	14.	Inheritance taxes; 

  

	 	15.	Gift taxes; 

  

	 	16.	Transfer taxes; 

  

	 	17.	Special assessments levied against other than Real Estate Assessments payable hereunder, while includable in Operating Expenses, shall be chargeable in installments if
the Landlord is permitted to do so. Furthermore, Tenant may upon ten (10) days’ notice to Landlord inspect or audit Landlord’s business records of Operating Expenses and if Tenant shall discover that Landlord has made an error of more
than five percent (5%) resulting in an overcharge to Tenant, then Landlord shall reimburse to Tenant, Tenant’s costs reasonably incurred for said audit; and 

 

	 	18.	Structural or foundation repairs required to maintain the structural integrity of the Building, but not normal exterior maintenance such as painting, drivit replacement
or repair etc. 

  
 8 

 SECTION 3.04 TAXES. 

(a) Landlord shall pay all real property taxes and assessments (all of which are hereinafter collectively referred to as
“Taxes”) which are levied against or which apply with respect to the Leased Premises. 
 (b) Tenant
shall prior to delinquency pay all taxes, assessments, charges, and fees which during the Rental Term hereof may be imposed, assessed, or levied by any governmental or public authority against or upon Tenant’s use of the Leased Premises or any
inventory, personal property, fixtures or equipment kept or installed, or permitted to be located therein by Tenant. 

SECTION 3.05 PAYMENTS. All payments of Base Monthly Rent, additional rent and other payments to be made to Landlord shall be made
on a timely basis and shall be payable to Landlord or as Landlord may otherwise designate. All such payments shall be mailed or delivered to Landlord’s principal office set forth in Section 1.01(C), or at such other place as Landlord may
designate from time to time in writing. If mailed, all payments shall be mailed in sufficient time and with adequate postage thereon to be received in Landlord’s account by no later than the due date for such payment. If Tenant shall fail to
pay any Base Monthly Rent or any additional rent or any other amounts or charges when due, Tenant shall pay interest from the due date of such past due amounts to the date of payment, both before and after judgment at a rate equal to the greater of
twelve (12%) percent per annum or two (2%) percent over the “prime” or “base” rate charged by Zion’s First National Bank of Utah at the due date of such payment; provided however, that in any case the maximum
amount or rate of interest to be charged shall not exceed the maximum non-usurious rate in accordance with applicable law. 

ARTICLE IV. RENTAL TERM, COMMENCEMENT DATE & PRELIMINARY TERM 

SECTION 4.01 RENTAL TERM. Subject to Tenant’s termination right set forth in Section 1.01(Z), the term of this Lease shall be
for the period defined as the Rental Term in Section 1.01(K), plus the partial calendar month, if any, occurring after the Rental Commencement Date (as hereinafter defined) if the Rental Commencement Date occurs other than on the first day of a
calendar month. “Lease Year” shall include twelve (12) calendar months, except that first Lease Year will also include any partial calendar month beginning on the Rental Commencement Date. 

SECTION 4.02 RENTAL COMMENCEMENT DATE. The Rental Term of this Lease and Tenant’s obligation to pay rent hereunder shall
commence as set forth in Section 1.01(K) (the “Rental Commencement Date”). Within five (5) days after Landlord’s request to do so, Landlord and Tenant shall execute a written affidavit, in recordable form, expressing the Rental
Commencement Date and the termination date, which affidavit shall be deemed to be part of this Lease. 
 SECTION 4.03
PRELIMINARY TERM. The period between the date Tenant enters upon the Leased Premises and the commencement of the Rental Term will be designated as the “preliminary term” during which no Base Monthly Rent shall accrue; however, other
covenants and obligations of Tenant shall be in full force and effect. Delivery of Possession of the Leased Premises to Tenant as provided in Section 5.03 shall be considered “entry” by Tenant and commencement of “preliminary
term”. 
 ARTICLE V. CONSTRUCTION OF LEASED PREMISES 

SECTION 5.01 CONSTRUCTION BY LANDLORD. Landlord shall construct or cause to be constructed the Building and Leased Premises
substantially in accordance with Outline Specifications set forth in Exhibit “C” attached hereto. Landlord’s construction obligation shall include Tenant Improvements pursuant to mutually agreed space layout plans and specifications
subject to the provisions of Article VI of this Lease. After consultation with Tenant, Landlord’s architect shall furnish the plans and specifications for the Leased Premises, but the cost thereof shall be charged toward Landlord Contribution.
It is understood and agreed by Tenant that no minor changes from any plans or from said Outline Specifications which may be necessary during construction of the Leased Premises or the Building shall affect or change this Lease or invalidate same.

  
 9 

 SECTION 5.02 CHANGES AND ADDITIONS BY LANDLORD. Landlord hereby reserves the right
at any time, and from time to time, to make alterations or additions to, and to build additional stories on the Building in which the Leased Premises are contained and to build adjoining the same and to modify the existing parking or other common
areas to accommodate additional buildings. Landlord also reserves the right to construct other buildings or improvements in the Building area from time to time, on condition that if the Building area is expanded so as to include any additional
buildings, Landlord agrees to create or maintain a parking ratio adequate to meet local laws and ordinances, including the right to add land to the Building or to erect parking structures thereon. 

SECTION 5.03 DELIVERY OF POSSESSION. Except as hereinafter provided, Landlord agrees to use good faith efforts to deliver the
Leased Premises, to Tenant in the condition called for in Exhibit “D”, on or before the date set forth in Section 1.01(J). The Leased Premises shall be deemed as ready for delivery when Landlord shall have substantially completed
construction of the portion of the said Leased Premises to be occupied exclusively by Tenant, in accordance with Landlord’s obligations set forth in Exhibit “D”. Landlord shall, from time to time during the course of construction,
provide information to Tenant concerning the progress of construction of said Leased Premises, and will give written notice to Tenant when said Leased Premises are in fact ready for Tenant’s occupancy. Notwithstanding the foregoing, Landlord
shall have the right to extend the date for delivery of possession of the Leased Premises for a period of one (1) month by notice in writing given to Tenant any time prior to said delivery date. If any disputes shall arise as to the Leased
Premises being ready for delivery of possession, a certificate furnished by Landlord’s architect in charge so certifying shall be conclusive and binding of that fact and date upon the parties. It is agreed that by occupying the Leased Premises
as a tenant, Tenant formally accepts the same and acknowledges that the Leased Premises are in the condition called for hereunder, except for items specifically excepted in writing within ten (10) business days of the date of occupancy as
“incomplete”. 
 ARTICLE VI. TENANT’S WORK & LANDLORD’S CONTRIBUTION 

SECTION 6.01 TENANT’S INITIAL IMPROVEMENTS. 

(a) Landlord shall provide Tenant’s Tenant Improvements as defined in Section H of Exhibit “C”. Landlord
shall provide at no charge, all space planning, architectural and mechanical drawings required to construct Tenant Improvements including construction drawings stamped by a licensed architect and submitted for approvals and permits. Tenant agrees to
cooperate and provide a representative to direct space planning efforts at such times as are requested by Landlord and shall give approvals or rejections of Tenant Improvement plans and specifications within five (5) days after submission by
Landlord’s architect. If Tenant fails to timely act as set forth in Article VI, then the time for delivery of possession shall be postponed appropriately. 
 (b) Tenant agrees to pay for all costs of Tenant Improvements and any other items installed by Tenant on the Leased Premises to the extent such costs exceed the amount of Landlord’s Contribution set
forth in Section 6.02 and 1.01(R). Prior to commencing construction of Tenant Improvements, Landlord shall obtain competitive bids from contractors mutually agreed upon between Landlord and Tenant. Tenant shall be entitled to review such bids and
mutually agree with Landlord as to the cost thereof. If the estimated cost exceeds Landlord’s Contribution, then Tenant shall deposit with Landlord the amount of such excess prior to commencement of construction. 

SECTION 6.02. Intentionally Omitted. 
 ARTICLE VII. USE 
 SECTION 7.01 USE OF LEASED PREMISES. Tenant shall
use and occupy the Leased Premises solely for the purpose of conducting the business indicated in Section 1.01(F). Tenant shall promptly comply with all present or future laws, ordinances, lawful orders and regulations affecting the Leased Premises
and the cleanliness, safety, occupancy and use of same. Tenant shall not make any use of the Leased Premises which Tenant has reason to know is likely to cause cancellation or an increase in the cost of any insurance policy covering

  
 10 

 
the same. Tenant shall not knowingly keep or use on the Leased Premises any article, item, or thing which is prohibited by the standard form of fire insurance policy. Tenant shall not commit any
waste upon the Leased Premises and shall not conduct or allow any business, activity, or thing on the Leased Premises which is an annoyance or causes damage to Landlord, to other subtenants, occupants, or users of the improvements, or to occupants
of the vicinity. 
 SECTION 7.02 HAZARDOUS SUBSTANCES. 

(a) Landlord shall be responsible for removal of any Hazardous Substances that existed at the Project prior to
construction or any that Landlord has or does install at the Leased Premises or Building. After reasonable inquiry, Landlord is not aware of any existing Hazardous Substances within the Project areas. 

(b) Tenant shall not use, produce, store, release, dispose or handle in or about the Leased Premises or transfer to or
from the Leased Premises (or permit any other party to do such acts) any Hazardous Substance except in compliance with all applicable Environmental Laws. Tenant shall not construct or use any improvements, fixtures or equipment or engage in any act
on or about the Leased Premises that would require the procurement of any license or permit pursuant to any Environmental Law. Tenant shall immediately notify Landlord of (i) the existence of any Hazardous Substance on or about the Leased
Premises that may be in violation of any Environmental Law (regardless of whether Tenant is responsible for the existence of such Hazardous Substance), (ii) any proceeding or investigation by any governmental authority regarding the presence of
any Hazardous Substance on the Leased Premises or the migration thereof to or from any other property, (iii) all claims made or threatened by any third party against Tenant relating to any loss or injury resulting from any Hazardous Substance,
or (iv) Tenant’s notification of the National Response Center of any release of a reportable quantity of a Hazardous Substance in or about the Leased Premises. “Environmental Laws” shall mean any federal, state or local statute,
ordinance, rule, regulation or guideline pertaining to health, industrial hygiene, or the environment, including without limitation, the federal Comprehensive Environmental Response, Compensation, and Liability Act; “Hazardous Substance”
shall mean all substances, materials and wastes that are or become regulated, or classified as hazardous or toxic, under any Environmental Law. If it is determined that any Hazardous Substance exists on the Leased Premises resulting from any act of
Tenant or its employees, agents, contractors, licensees, subtenants or customers, then Tenant shall immediately take necessary action to cause the removal of said substance and shall remove such within ten (10) days after discovery.
Notwithstanding the above, if the Hazardous Substance is of a nature that cannot be reasonably removed within ten (10) days Tenant shall not be in default if Tenant has commenced to cause such removal and proceeds diligently thereafter to
complete removal, except that in all cases, any Hazardous Substance must be removed within sixty (60) days after discovery thereof. Furthermore, notwithstanding the above, if in the good faith judgment of Landlord, the existence of such
Hazardous Substance creates an emergency or is of a nature which may result in immediate physical danger to persons at the Property, Landlord may enter upon the Leased Premises and remove such Hazardous Substances and charge the cost thereof to
Tenant as Additional Rent. 
 (c) The party herein responsible for removal of Hazardous Substances shall upon
learning of such condition proceed within five (5) days thereafter to commence removal of such Hazardous Substance and shall diligently continue to effect such removal until completion. Removal shall be accomplished in accordance with any
applicable safety standards. 
 ARTICLE VIII. OPERATION AND MAINTENANCE OF COMMON AREAS. 

SECTION 8.01 CONSTRUCTION AND CONTROL OF COMMON AREAS. All automobile parking areas, driveways, entrances and exits thereto, and
other facilities furnished by Landlord in or near the buildings or Building, including if any, employee parking areas, truck ways, loading docks, mail rooms or mail pickup areas, pedestrian sidewalks and hallways, landscaped areas, retaining walls,
stairways, restrooms and other areas and improvements provided by Landlord for the general use in common tenants, their officers, agents, employees and customers, shall at all times be subject to the exclusive control and management of

  
 11 

 
Landlord which shall have the right from time to time to establish, modify and enforce reasonable Rules and Regulations with respect to all facilities and areas mentioned in this Section.
Landlord shall have the right to construct, maintain and operate lighting and drainage facilities on or in all said areas and improvements; to police the same, from time to time to change the area, level, location and arrangement of parking areas
and other facilities hereinabove referred to; to restrict parking by tenants, their officers, agents and employees to employee parking areas; to close temporarily all or any portion of said areas or facilities to such extent as may, in the opinion
of counsel, be legally sufficient to prevent a dedication thereof or the accrual of any rights to any person or the public therein; to assign “reserved” parking spaces for exclusive use of certain tenants or for customer parking, to
discourage non-employee and non-customer parking; and to do and perform such other acts in and to said areas and improvements as, in the exercise of good business judgment, the Landlord shall determine to be advisable with a view toward maintaining
of appropriate convenience uses, amenities, and for permitted uses by tenants, their officers, agents, employees and customers. Landlord will operate and maintain the common facilities referred to above in such a manner as it, in its sole
discretion, shall determine from time to time. Without limiting the scope of such discretion, Landlord shall have the full right and authority to employ all personnel and to make all Rules and Regulations pertaining to and necessary for the proper
operation, security and maintenance of the common areas and facilities. Building and/or project signs, traffic control signs and other signs determined by Landlord to be in best interest of the Building, will be considered part of common area and
common facilities. 
 SECTION 8.02 LICENSE. All common areas and facilities not within the Leased Premises, which Tenant
may be permitted to use and occupy, are to be used and occupied under a revocable license, and if the amount of such areas be diminished, Landlord shall not be subject to any liabilities nor shall Tenant be entitled to any compensation or diminution
or abatement of rent, nor shall such diminution of such areas be deemed constructive or actual eviction, so long as such revocations or diminutions are deemed by Landlord to serve the best interests of the Building. 

SECTION 8.03 AUDIT. Tenant shall have the right, not more frequently than once every two (2) calendar years, to audit (the
“CAM Audit”) all of Landlord’s or Landlord’s agent’s records pertaining to Common Area Charges for the prior two (2) Lease Years. Tenant shall not be permitted to utilize a so-called “contingent fee” CAM
auditor. Accordingly, any representative of Tenant conducting, assisting, or having any involvement with the CAM Audit shall not be permitted to have a financial stake in the outcome of the CAM audit and Landlord shall be entitled to receive
credible evidence of the same and Landlord may refuse to allow such CAM audit in the absence of such evidence. Additionally, any representative of Tenant conducting a CAM audit shall first sign a confidentiality agreement that provides that it will
not disclose the audit, its conclusions or any information obtained in the course of conducting the audit to anyone other than Tenant and Landlord. 
 Landlord shall retain its records regarding Common Area Charges for a period of at least two (2) years following the final billing for each calendar year during the Term. At any time during such two
(2) year period, upon thirty (30) days’ advance written notice to Landlord, Tenant may conduct a CAM Audit. The CAM Audit shall commence on a date of which Tenant has notified Landlord not less than thirty (30) days in advance.
Tenant shall in all cases share with Landlord the conclusions of the CAM Audit and/or any CAM Audit report. If the CAM Audit discloses an overbilling, Landlord may, by written notice to Tenant within forty-five (45) days of Landlord’s
receipt of a copy of the CAM Audit, object to the conclusions or process of the CAM Audit, stating its conclusions as to whether or not there was any overbilling (and if so, the amount thereof). If Tenant disputes Landlord’s conclusions, Tenant
shall notify Landlord and the parties shall use good faith efforts to resolve the dispute. If Landlord agrees with the CAM Audit, Landlord shall pay to Tenant the amount of the overbilling within forty-five (45) days of Landlord’s receipt
of a copy of the CAM Audit. If the CAM Audit discloses an underbilling, Tenant shall pay to Landlord the amount of the underbilling within forty-five (45) days of Tenant’s receipt of a copy of the CAM Audit or its conclusions. 

ARTICLE IX. ALTERATIONS, SIGNS, LOCKS & KEYS 
 SECTION 9.01 ALTERATIONS. Tenant shall not make or suffer to be made any alterations or additions to the Leased Premises or any part thereof without the prior written consent of Landlord. Any
additions to, or alterations of the Leased Premises except movable furniture, equipment and trade fixtures shall become a part of the realty and belong to Landlord 

  
 12 

 
upon the termination of Tenant’s lease or renewal term or other termination or surrender of the Leased Premises to Landlord. 

SECTION 9.02 SIGNS. Tenant shall not place or suffer to be placed or maintained on any exterior door, wall or window of the Leased
Premises, or elsewhere in the Building, any sign, awning, marquee, decoration, lettering, attachment, canopy, advertising matter or other thing of any kind, and will not place or maintain any decoration, lettering or advertising matter on the glass
of any window or door of the Leased Premises without first obtaining Landlord’s written approval. Tenant shall maintain any such sign, awning, canopy, decoration, lettering, advertising matter or other things as may be approved in good
condition and repair at all times. Landlord may, at Tenant’s cost, and without liability to Tenant, enter the Leased Premises and remove any item erected in violation of the Section 9.02. Landlord has established rules and regulations governing
the size, type and design of all signs, decorations, etc., which is specifically set forth in Exhibit “E” attached hereto and by this reference incorporated herein. 
 SECTION 9.03 LOCKS AND KEYS. Landlord shall install a card key system for access to the Building and covered parking area and shall issue appropriate card keys to Tenant and Tenant’s
authorized employees. Landlord shall initially provide keys for entry doors to the Leased Premises. From time to time, Tenant may change locks or install other locks on doors, but if Tenant does, Tenant must provide Landlord with duplicate keys
within twenty four hours after said change or installation. Tenant upon termination of this Lease shall deliver to Landlord all the keys to the Building and Leased Premises including any interior offices, toilet rooms, combinations to built-in
safes, etc. which shall have been furnished to or by the Tenant or are in the possession of the Tenant. 
 ARTICLE X.
MAINTENANCE AND REPAIRS; ALTERATIONS; ACCESS 
 SECTION 10.01 LANDLORD’S OBLIGATION FOR MAINTENANCE. Landlord
shall maintain and repair: (1) the areas outside the Leased Premises including hallways, public restrooms, if any, general landscaping, parking areas, driveways and walkways; (2) the Building roof, and foundation; and (3) all
plumbing, electrical, heating, and air conditioning systems. However, to the extent the need for such repairs or maintenance results from any wrongful or negligent act or omission of Tenant, Tenant shall pay the entire cost of any such repair or
maintenance. Landlord shall not be obligated to repair any damage or defect until the earlier of (i) Landlord’s receipt of written notice from Tenant of the need of such repair or (ii) Landlord has actual or constructive knowledge of
the need of such repair, and Landlord shall have a reasonable time thereafter in which to make such repairs. Tenant shall give immediate notice to Landlord in case of fire or accidents in the Leased Premises or in the building of which the Leased
Premises are a part or of defects therein or in any fixtures or equipment provided by Landlord. Costs of Landlord-provided maintenance for Item 2 herein shall be included as Operating Expenses as defined in Section 3.03(d) and (e) herein.

 SECTION 10.02 TENANT’S OBLIGATION FOR MAINTENANCE. 

(a) Tenant shall provide its own janitorial service and keep and maintain the Leased Premises including the interior wall
surfaces and windows, floors, floor coverings and ceilings in a clean, sanitary and safe condition in accordance with the laws of the State and in accordance with all directions, rules and regulations of the health officer, fire marshal, building
inspector, or other proper officials of the governmental agencies having jurisdiction, at the sole cost and expense of Tenant, and Tenant shall comply with all requirements of law, ordinance and otherwise, affecting said Leased Premises. 

(b) Tenant shall pay, when due, all claims for labor or material furnished, for work under Sections 9.01, 9.02 and 10.02
hereof, to or for Tenant at or for use in the Leased Premises, and shall bond such work if reasonably required by Landlord to prevent assertion of claims against Landlord. 

(c) Tenant agrees to be responsible for all furnishings, fixtures and equipment located upon the Leased Premises from time
to time and shall replace carpeting within the Leased 

  
 13 

 
Premises if same shall be damaged by tearing, burning, or stains resulting from spilling anything on said carpet, reasonable wear and tear accepted. 

SECTION 10.03 SURRENDER AND RIGHTS UPON TERMINATION. 

(a) This Lease and the tenancy hereby created shall cease and terminate at the end of the Rental Term hereof, or any
extension or renewal thereof, without the necessity of any notice form either Landlord or Tenant to terminate the same, and Tenant hereby waives notice to vacate the Leased Premises and agrees that Landlord shall be entitled to the benefit of all
provisions of law respecting summary recovery of possession of Leased Premises from a Tenant holding over to the same extent as if statutory notice has been given. 

(b) Upon termination of this Lease at any time and for any reason whatsoever, Tenant shall surrender and deliver up the
Leased Premises to Landlord in the same condition as when the Leased Premises were delivered to Tenant or as altered as provided in Section 9.01, ordinary wear and tear excepted. Upon request of Landlord, Tenant shall promptly remove all personal
property from the Leased Premises and repair any damage caused by such removal. Obligations under this Lease relating to events occurring or circumstances existing prior to the date of termination shall survive the expiration or other termination of
the Rental Term of this Lease. Liabilities accruing after date of termination are defined in Sections 13.05, 19.01 and 19.02. 

ARTICLE XI. INSURANCE AND INDEMNITY 
 SECTION 11.01 LIABILITY INSURANCE AND INDEMNITY. Tenant shall, during all terms hereof, keep in full force and effect a policy of public bodily injury and property damage liability insurance with
respect to the Leased Premises, with a combined single limit of not less than Two Million Dollars ($2,000,000.00) per occurrence. The policy shall name Landlord, property manager (i.e., Woodbury Corporation) and any other persons, firms or
corporations designated by Landlord and Tenant as additional insureds, and shall contain a clause that the insurer will not cancel or change the insurance without first giving the Landlord ten (10) days prior written notice. Such insurance
shall include an endorsement permitting Landlord and Property Manager to recover damage suffered due to act or omission of Tenant, notwithstanding being named as an additional “Insured party” in such policies. Such insurance may be
furnished by Tenant under any blanket policy carried by it or under a separate policy therefor. The insurance shall be with an insurance company approved by Landlord and a copy of the paid-up policy evidencing such insurance or a certificate of
insurer certifying to the issuance of such policy shall be delivered to Landlord; provided, Landlord shall not unreasonably withhold its approval of Tenant’s selected insurance company. If Tenant fails to provide such insurance, Landlord may do
so and charge actual costs of same to Tenant. 
 Tenant will indemnify, defend and hold Landlord harmless from and against any
and all claims, actions, damages, liability and expense in connection with loss of life, personal injury and/or damage to property arising from or out of any occurrence in, upon or at the Leased Premises or from the occupancy or use by Tenant of the
Leased Premises or any part thereof, or occasioned wholly or in part by any act or omission of Tenant, its agents, contractors, employees, servants, sublessees, concessionaires or business invitees except to the extent caused by the negligence of
Landlord and to the extent not covered by its fire casualty or liability insurance. In case Landlord shall, without fault of its part, be made a party to any litigation commenced by or against Tenant, then Tenant shall protect and hold Landlord
harmless and shall pay all costs, expenses and reasonable attorney fees incurred or paid by either in defending itself or enforcing the covenants and agreements of this Lease. 
 Landlord will indemnify, defend and hold Tenant harmless from and against any and all claims, actions, damages, liability and expense in connection with loss of life, personal injury and/or damage to
property arising from or out of any occurrence in, upon or at the common area or from the occupancy or use by Landlord of the common area or any part thereof, or occasioned wholly or in part by any act or omission of Landlord, its agents,
contractors, employees, servants, sublessees, concessionaires or business invitees unless caused by the negligence of Tenant and to the extent not covered by its casualty or liability insurance. In case Tenant shall, without fault of its part, be
made a party to any litigation commenced by or against Landlord, then Landlord shall protect and hold Tenant harmless and shall pay all costs, 

  
 14 

 
expenses and reasonable attorney fees incurred or paid by either in defending itself or enforcing the covenants and agreements of this Lease. 

SECTION 11.02 FIRE AND CASUALTY INSURANCE. 

(a) Subject to the provisions of this Section 11.02, Landlord shall secure, pay for, and at all times during the terms
hereof maintain “All Risk” casualty, insurance providing coverage upon the building improvements in an amount equal to the full insurable replacement value thereof (as determined by Landlord). Said insurance shall include twelve
(12) months rental income coverage as well as such additional endorsements as may be required by Landlord’s Lender or Landlord. All insurance required hereunder shall be written by reputable, responsible companies licensed in the State of
Utah. Tenant shall have the right, at its request at any reasonable time, to be furnished with copies of the insurance policies then in force pursuant to this Section, together with evidence that the premiums therefor have been paid. 

(b) Tenant agrees to maintain at its own expense such fire and casualty insurance coverage as Tenant may desire or require
in respect to Tenant’s personal property, equipment, furniture, fixtures or inventory and Landlord shall have no obligation in respect to such insurance or losses. All property kept or stored on the Leased Premises by Tenant or with
Tenant’s permission shall be so done at Tenant’s sole risk and Tenant shall indemnify Landlord against and hold it harmless from any claims arising out of loss or damage to same. 

(c) If Tenant installs any electrical or other equipment which overloads the lines in the Leased Premises, Tenant shall at
its own expense make whatever changes are necessary to comply with the requirements of Landlord’s insurance. 
 (d) Tenant shall be responsible for all glass breakage from any cause whatsoever and agrees to immediately replace all glass broken or damaged during the terms hereof with glass of the same quality as
that broken or damaged. Landlord may replace, at Tenant’s expense, any broken or damaged glass if not replaced by Tenant within five (5) days after such damage. 
 SECTION 11.03 WAIVER OF SUBROGATION. Each party hereto does hereby release and discharge the other party hereto and any officer, agent, employee or representative of such party, of and from any
liability whatsoever hereafter arising from loss, damage or injury caused by fire or other casualty for which insurance (permitting waiver of liability and containing a waiver of subrogation) is carried by the injured party at the time of such loss,
damage or injury to the extent of any recovery by the injured party under such insurance. 
 ARTICLE XII UTILITY CHARGES

 SECTION 12.01 OBLIGATION OF LANDLORD. Unless otherwise agreed in writing by the parties, during the term of this
Lease the Landlord shall cause to be furnished to the Leased Premises during “standard operating hours” which shall be 7:00 a.m. to 6:30 p.m. Monday through Friday and 8:00 a.m. to 12:00 Noon on Saturday, excluding holidays on which banks
in the state are permitted to be closed, the following utilities and services, the cost and expense of which shall be included in Operating Expenses: 
 (a) Electricity, water, gas and sewer service. 
 (b) Telephone
connection, but not including telephone stations and equipment (it being expressly understood and agreed that Tenant shall be responsible for the ordering and installation of telephone lines and equipment which pertain to the Leased Premises).

 (c) Heat and air-conditioning to such extent and to such levels as is reasonably required for the comfortable
use and occupancy of the Leased Premises subject however to any limitations imposed by any government agency. 

(d) Snow removal and parking lot sweeping services. 

  
 15 

 (e) Elevator service. 

(f) Building systems maintenance services. 
 SECTION 12.02 OBLIGATIONS OF TENANT. Tenant shall arrange for and shall pay the entire cost and expense of all telephone stations, equipment and use charges, electric light bulbs (but not
fluorescent bulbs used in fixtures originally installed in the Leased Premises) and all other materials and services not expressly required to be provided and paid for pursuant to the provisions of Section 12.01 above. Tenant covenants to use good
faith efforts to reasonably conserve utilities by turning off lights and equipment when not in use and taking such other reasonable actions in accordance with sound standards for energy conservation. Landlord reserves the right to separately meter
or otherwise monitor any utility usage and to separately charge Tenants for its own utilities, in which case an equitable adjustment shall be made to Base Rental and Tenant’s share of Operating Expenses as set forth in this Lease. Additional
limitations of Tenant are as follows: 
 (a) Tenant will not, without the written consent of Landlord, which
consent shall not be unreasonably withheld, use any apparatus or device on the Leased Premises using current in excess of 208 volts which will in any way or to any extent increase the amount of electricity or water usually furnished or supplied for
use on the Leased Premises for the use designated in Section 7.01 above, nor connect with electrical current, except through existing electrical outlets in the Leased Premises, or water pipes, any apparatus or device, for the purposes of using
electric current or water. 
 (b) If Tenant shall require water or electric current in excess of that usually
furnished or supplied for use of the Leased Premises, or for purposes other than those designated in Section 7.01 above, Tenant shall first procure the written consent of Landlord for the use thereof, which consent Landlord may refuse and/or
Landlord may cause a water meter or electric current meter to be installed in the Leased Premises, so as to measure the amount of water and/or electric current consumed for any such use. The cost of such meters and of installation maintenance, and
repair thereof shall be paid for by Tenant and Tenant agrees to pay Landlord promptly upon demand by Landlord for all such water and electric current consumed as shown by said meters, at the rates charged for such service by the City in which the
Building is located or the local public utility, as the case may be, furnishing the same, plus any additional expense incurred in keeping account of the water and electric current so consumed. 

(c) If and where heat generating machines devices are used in the Leased Premises which affect the temperature otherwise
maintained by the air conditioning system, Landlord reserves the right to install additional or supplementary air conditioning units for the Leased Premises, and the entire cost of installing, operating, maintaining and repairing the same shall be
paid by Tenant to Landlord promptly after demand by Landlord. 
 To the extent that Tenant operates hours in
excess of the stated standard business hours, Tenant may cause Landlord to provide services set forth in Section 12.01 (a), (b), (c) and (e) above; however, Tenant shall pay extra hourly utility charges as set forth in Section 1.01(P) and
Section 12.03 herein. 
 SECTION 12.03. EXTRA HOURS CHARGES. To the extent Tenant operates hours other than “normal
operating hours” as set forth in Section 12.01, Tenant shall pay an extra hourly utility charge of $0.25 per hour per 1,000 square feet for lighting and electricity and $5.00 per hour per 1,000 square feet for mechanical/HVAC system for each
full or partial hour during which Tenant operates. Tenant shall pay such charges within ten (10) days after invoice therefor. Costs incurred by Landlord for operating “extra-hours” shall not be included in Operating Expenses pursuant
to Section 3.03. 
 SECTION 12.04. LIMITATIONS ON LANDLORDS LIABILITY. Landlord shall not be liable for and Tenant shall
not be entitled to terminate this Lease or to effectuate any abatement or reduction of rent by reason of Landlord’s failure to provide or furnish any of the foregoing utilities or services if such failure was reasonably beyond the control of
Landlord. In no event shall Landlord be liable for loss or injury to persons or damage to property, however, arising or occurring in connection with or attributable to any failure to furnish such utilities or services even if within the control of
Landlord. 

  
 16 

 ARTICLE XIII. OFF-SET STATEMENT, ATTORNMENT AND SUBORDINATION 

SECTION 13.01 OFF-SET STATEMENT. Tenant agrees within ten (10) days after request therefor by Landlord to execute in
recordable form and deliver to Landlord a statement in writing, certifying 
 (a) that this Lease is in full
force and effect; 
 (b) the date of commencement of the Rental Term of this Lease; 

(c) that rent is paid currently without any off-set or defense thereto; 

(d) the amount of rent, if any paid in advance; and 

(e) that there are no uncured defaults by Landlord or stating those claimed by Tenant. 

Such statement shall only be required once during any twelve (12) month period during the Rental Term. 

SECTION 13.02 ATTORNMENT. Tenant shall, in the event any proceedings are brought for the foreclosure of, or in the event of
exercise of the power of sale under any mortgage or deed of trust made by Landlord covering the Leased Premises, attorn to the purchaser upon any such foreclosure or sale and recognize such purchaser as the Landlord under this Lease. 

SECTION 13.03 SUBORDINATION. Tenant agrees that this Lease shall, at the request of Landlord, be subordinate to any first
mortgages or deeds of trust that may hereafter be placed upon said Leased Premises and to any and all advances to be made thereunder, and to the interest thereon, and all renewals, replacements and extensions thereof, provided the mortgagees or
trustees named in said mortgages or deeds of trust shall agree to recognize the Lease of Tenant in the event of foreclosure, if Tenant is not in default. 
 SECTION 13.04 MORTGAGEE SUBORDINATION. Tenant hereby agrees that this Lease shall, if at any time requested by Landlord or any lender in respect to Landlord’s financing of the Building or
Project in which the Leased Premises are located or any portion hereof, be made superior to any mortgage or deed of trust that may have preceded such Lease. 
 SECTION 13.05 REMEDIES. Tenant hereby irrevocably appoints Landlord as attorney-in-fact for the Tenant with full power and authority to execute and deliver in the name of the Tenant any such
instruments described in this Article XIII upon failure of the Tenant to execute and deliver any of the above instruments within fifteen (15) days after written request so to do by Landlord; and such failure shall constitute a breach of this
Lease entitling the Landlord, at its option, to cancel this Lease and terminate the Tenant’s interest therein. 
 ARTICLE
XIV. ASSIGNMENT 
 SECTION 14.01 ASSIGNMENT. Tenant shall not assign this Lease or sublet the Leased Premises, or any
part thereof, without first obtaining the written consent of the Landlord, which consent shall not be unreasonably withheld, conditioned or delayed. The consent of Landlord shall not relieve Tenant of this Lease from continuing liability for all
obligations under this Lease. Any Assignment by operation of law or if the Tenant be a corporation, unincorporated association or partnership, the transfer, assignment or hypothecation of any stock or interest in such corporation, association or
partnership in the aggregate in excess of fifty percent (50%) shall be deemed an “Assignment” within the meaning of this Section. Notwithstanding the foregoing, any assignment by Tenant to a parent corporation, or to a successor
corporation acquiring substantially all the assets of Tenant, and intending to operate Tenant’s business under the same trade name, will be deemed a permitted assignment not requiring Landlord’s consent. 

  
 17 

 ARTICLE XV. WASTE OR NUISANCE 

SECTION 15.01 WASTE OR NUISANCE. Tenant shall not commit or suffer to be committed any waste upon the Leased Premises, or any
nuisance or other act or thing which may disturb the quiet enjoyment of any other tenant in the Building in which the Leased Premises may be located, or elsewhere within the Building. 

ARTICLE XVI. NOTICES 
 SECTION 16.01 NOTICES. Except as provided in Section 19.01, any notice required or permitted hereunder to be given or transmitted between the parties shall be either 1) personally delivered, or 2)
mailed postage prepaid by registered mall, return receipt requested, or mailed by express carrier addressed if to Tenant at the address set forth in Section 1.01(E), and if to Landlord at the address set forth in Section 1.01(C). Either party may,
by written notice to the other given as prescribed in this Section 16.01, change its above address for any future notices which are mailed under this Lease. 
 ARTICLE XVII. DESTRUCTION OF THE LEASED PREMISES 
 SECTION 17.01
DESTRUCTION. 
 (a) If the Leased Premises are partially or totally destroyed by fire or other casualty
insurable under standard fire insurance policies with extended coverage endorsement so as to become partially or totally untenantable, the same shall be repaired or rebuilt as speedily as practical under the circumstances at the expense of the
Landlord, unless Landlord elects not to repair or rebuild as provided in Subsection (b) of this Section 17.01. During the period required for restoration, a just and proportionate part of Base Monthly Rent, Additional Rent and other charges
payable by Tenant hereunder shall be abated until the Leased Premises are repaired or rebuilt. 
 (b) If the
Leased Premises are (I) rendered totally untenantable by reason of an occurrence described in Subsection (a), or (II) damaged or destroyed as a result of a risk which is not insured under Landlord’s fire insurance policies, or (III) at
least twenty percent (20%) damaged or destroyed during the last year of the Rental Term, or (IV) if the Building is damaged in whole or in part (whether or not the Leased Premises are damaged), to such an extent that Tenant cannot practically
use the Leased Premises for its intended purpose, then and in any such events either party may terminate this Lease by notice in writing to the other party within sixty (60) days after the date of such occurrence. Unless either party gives such
notice, this Lease will remain in full force and effect and Landlord shall repair such damage at its expense as expeditiously as possible under the circumstances. 

(c) If Landlord should elect or be obligated pursuant to Subsection (a) above to repair or rebuild because of any
damage or destruction, Landlord’s obligation shall be limited to the original Building any other work or improvements which may have been originally performed or installed at Landlord’s expense. If the cost of performing Landlord’s
obligation exceeds the actual proceeds of insurance paid or payable to Landlord on account of such casualty, Landlord may terminate this Lease unless Tenant, within fifteen (15) days after demand therefor, deposits with Landlord a sum of money
sufficient to pay the difference between the cost of repair and the proceeds of the insurance available for such purpose. Tenant shall replace all work and improvements not originally installed or performed by Landlord at its expense. 

(d) Except as stated in this Article XVII, and for acts of gross negligence or willful misconduct, Landlord shall not be
liable for any loss or damage sustained by Tenant by reason of casualties mentioned hereinabove or any other accidental casualty. 

  
 18 

 ARTICLE XVIII. CONDEMNATION 

SECTION 18.01 CONDEMNATION. As used in this Section the term “Condemnation Proceeding” means any action or proceeding in
which any interest in the Leased Premises or Building is taken for any public or quasi-public purpose by any lawful authority through exercise of the power of eminent domain or right of condemnation or by purchase or otherwise in lieu thereof. If
the whole of the Leased Premises is taken through Condemnation Proceedings, this Lease shall automatically terminate as of the date possession is taken by the condemning authority. If in excess of twenty-five (25%) percent of the Leased
Premises is taken, either party hereto shall have the option to terminate this Lease by giving the other written notice of such election at any time within thirty (30) days after the date of taking. If less than twenty-five (25%) percent
of the space is taken and Landlord determines, in Landlord’s sole discretion, that a reasonable amount of reconstruction thereof will not result in the Leased Premises or the Building becoming a practical improvement reasonably suitable for use
for the purpose for which it is designed, then Landlord may elect to terminate this Lease by giving thirty (30) days written notice as provided hereinabove. In all other cases, or if neither party exercises its option to terminate, this Lease
shall remain in effect and the rent payable hereunder from and after the date of taking shall be proportionately reduced in proportion to the ratio of: (1) the area contained in the Leased Premises which is capable of occupancy after the
taking; to (II) the total area contained in the Leased Premises which was capable of occupancy prior to the taking. In the event of any termination or rental reduction provided for in this Section, there shall be a proration of the rent payable
under this Lease and Landlord shall refund any excess theretofore paid by Tenant. Whether or not this Lease is terminated as a consequence of Condemnation Proceedings, all damages or compensation awarded for a partial or total taking, including any
sums compensating Tenant for diminution in the value of or deprivation of its leasehold estate, shall be the sole and exclusive property of Landlord, except that Tenant will be entitled to any awards intended to compensate Tenant for expenses of
locating and moving Tenant’s operations to a new space, including personal business equipment. 
 ARTICLE XIX. DEFAULT OF
TENANT 
 SECTION 19.01 DEFAULT—RIGHT TO RE-ENTER. In the event of any failure of Tenant to pay any rental due
hereunder within ten (10) days after written notice that the same is past due shall have been mailed to Tenant, or any failure by Tenant to perform any other of the terms, conditions or covenants required of Tenant by this Lease within thirty
(30) days after written notice of such default shall have been mailed to Tenant (unless it is not reasonable to have such failure cured within such thirty (30) day period, in which case Tenant shall have made substantial progress towards
curing such failure with in such thirty (30) day period) (the “Cure Period”) or if Tenant shall abandon said Leased Premises, or permit this Lease to be taken under any writ of execution. At the end of the Cure Period, then Landlord,
besides other rights or remedies it may have, shall have the right to declare this Lease terminated and shall have the immediate right of re-entry and may remove all persons and property from the Leased Premises. Such property may be removed and
stored in a public warehouse or elsewhere at the cost of and for the account of Tenant, without evidence of notice or resort to legal process and without being deemed guilty of trespass, or becoming liable for any loss or damage which may be
occasioned thereby. Tenant hereby waives all compensation for the forfeiture of the term or its loss of possession of the Leased Premises in the event of the forfeiture of this Lease as provided for above. 

SECTION 19.02 DEFAULT—RIGHT TO RE-LET. Should Landlord elect to re-enter, as herein provided, or should it take possession
pursuant to legal proceedings or pursuant to any notice provided for by law, it may either terminate this Lease or it may from time to time, without terminating this Lease, make such alterations and repairs as may be necessary in order to re-let the
Leased Premises, and may re-let said Leased Premises or any part thereof for such term or terms (which may be for a term extending beyond the term of this Lease) and at such rental or rentals and upon such other terms and conditions as Landlord in
its sole discretion may deem advisable. Upon each such re-letting, all rentals received by Landlord from such re-letting shall be applied first to the payment of any costs and expenses of such re-letting, including brokerage fees and attorney’s
fees and costs of such alterations and repairs; second, to the payment of rent or other unpaid obligations due hereunder; and the residue, if any, shall be held by Landlord and applied in payment of future rent as the same may become due and payable
hereunder. If such rental received from such re-letting during any month be less than that to be paid during that month by Tenant hereunder, Tenant shall pay any such deficiency to Landlord. Such deficiency shall be calculated and paid monthly. No
such re-entry or taking possession of said Leased Premises by Landlord shall be construed as an election on its part to terminate this Lease unless a written notice of such intention is given to Tenant or unless the termination thereof be decreed by
a court or competent jurisdiction. Notwithstanding any such 

  
 19 

 
re-letting without termination, Landlord may at any time elect to terminate this Lease for such previous default. Should Landlord at any time terminate this Lease for any default, in addition to
any other remedies it may have, it may recover from Tenant all damages it may incur by reason of such default, including the cost of recovering the Leased Premises, reasonable attorney’s fees, and including the worth at the time of such
termination of the excess, if any, of the amount of rent and charges equivalent to rent reserved in this Lease for the remainder of the stated term over the then reasonable rental value of the Leased Premises for the remainder of the stated term,
all of which amounts shall be immediately due and payable. 
 SECTION 19.03 LEGAL EXPENSES. In case of default by either
party in the performance and obligations under this Lease, the defaulting party shall pay all costs incurred in enforcing this Lease, or any right arising out of such default, whether by suit or otherwise, including a reasonable attorney’s fee.

 ARTICLE XX. BANKRUPTCY, INSOLVENCY OR RECEIVERSHIP 

SECTION 20.01 ACT OF INSOLVENCY, GUARDIANSHIP, ETC. The following shall constitute a default of this Lease by the Tenant for which
Landlord, at Landlord’s option, may immediately terminate this Lease. 
 (a) The appointment of a receiver
to take possession of all or substantially all of the assets of the Tenant. 
 (b) A general assignment by the
Tenant of his assets for the benefit of creditors. 
 (c) Any action taken or suffered by or against the Tenant
under any federal or state insolvency or bankruptcy act. 
 (d) The appointment of a guardian, conservator,
trustee, or other similar officer to take charge of all or any substantial part of the Tenant’s property. 
 Neither this
Lease, nor any interest therein nor any estate thereby created shall pass to any trustee, guardian, receiver or assignee for the benefit of creditors or otherwise by operation of law. 

ARTICLE XXI. LANDLORD ACCESS 
 SECTION 21.01 LANDLORD ACCESS. Landlord or Landlord’s agent shall have the right to enter the Leased Premises upon two (2) days’ prior written notice and at reasonable times to
examine the same, or to show them to prospective purchasers or lessees of the Building, or to make all repairs, alterations, improvements or additions as Landlord may deem necessary or desirable, and Landlord shall be allowed to take all material
into and upon said Leased Premises that may be required therefor without the same constituting an eviction of Tenant in whole or in part, and rent shall not abate while said repairs, alterations, improvements, or additions are being made, by reason
of loss or interruption of business of Tenant, or otherwise upon a mutually reasonably agreed upon time by both Landlord and Tenant. During the ninety (90) days prior to the expiration of the Rental Term of this Lease or any renewal term,
Landlord may exhibit the Leased Premises to prospective tenants and place upon the Leased Premises the usual notices “To Let” or “For Rent” which notices Tenant shall permit to remain thereon with molestation. 

ARTICLE XXII. LANDLORD’S LIEN 
 SECTION 22.01 LANDLORD’S LIEN. Tenant acknowledges that as of the date hereof, Utah Code Section 38-3-1 and following may grant Landlord a lien upon certain improvements, trade fixtures and
furnishings of Tenant in regard to unpaid rent. So long as Tenant is not in default under this Lease, Landlord will agree to subordinate any such lien to any bonafide, third-party lender with regards to the Leased Premises. 

  
 20 

 ARTICLE XXIII. HOLDING OVER 

SECTION 23.01 HOLDING OVER. Any holding over after the expiration of the Rental Term hereof shall be construed to be a tenancy at
sufferance and all provisions of this Lease shall be and remain in effect except that the monthly rental shall be one hundred twenty percent (120%) of rent (including any adjustments as provided herein) payable for the last full calendar month
of the Rental Term including renewals or extensions. 
 SECTION 23.02 SUCCESSORS. All rights and liabilities herein given
to, or imposed upon, the respective parties hereto shall extend to and bind the several respective heirs, executors, administrators, successors and assigns of the said parties; and if there shall be more than one tenant, they shall all be bound
jointly and severally by the terms, covenants and agreements herein. No rights, however, shall inure to the benefit of any assignee of Tenant unless the assignment to such assignee has been approved by Landlord in writing. 

ARTICLE XXIV. RULES AND REGULATIONS 
 SECTION 24.01 RULES AND REGULATIONS. Tenant shall comply with all reasonable rules and regulations which are now or which may be hereafter prescribed by the Landlord and posted in or about said
Leased Premises or otherwise brought to the notice of the Tenant, both with regard to the project as a whole and to the Leased Premises including common facilities. 
 ARTICLE XXV. QUIET ENJOYMENT 
 SECTION 25.01 QUIET ENJOYMENT. Upon
payment by the Tenant of the rents herein provided, and upon the observance and performance of all the covenants, terms and conditions on Tenant’s part to be observed and performed, Tenant shall peaceably and quietly hold and enjoy the Leased
Premises for the term hereby demised without hindrance or interruption by Landlord or any other person or persons lawfully or equitably claiming by, through or under the Landlord, subject, nevertheless, to the terms and conditions of this Lease and
actions resulting from future eminent domain proceedings and casualty losses. 
 ARTICLE XXVI. SECURITY DEPOSIT

 SECTION 26.01 SECURITY DEPOSIT. The Landlord herewith acknowledges receipt of the amount set forth in Section 1.01
(U) which it is to retain as security for the faithful performance of all the covenants, conditions and agreements of this Lease, but in no event shall the Landlord be obliged to apply the same upon rents or other charges in arrears or upon
damages for the Tenant’s failure to perform the said covenants, conditions and agreements; the Landlord may so apply the Security Deposit, at its option; and the Landlord’s right to the possession of the Leased Premises for non-payment of
rents or for other reasons shall not in any event be affected by reason of the fact that the Landlord holds this Security Deposit. The said sum, if not applied toward the payment of rents in arrears or toward the payment of damages suffered by the
Landlord by reason of the Tenant’s breach of the covenants, conditions and agreements of this Lease, is to be returned to Tenant without interest when this Lease is terminated, according to these terms, and in no event is the Security Deposit
to be returned until Tenant has vacated the Leased Premises and delivered possession to the Landlord. 
 In the event that the
Landlord repossesses Leased Premises because of the Tenant’s default or because of the Tenant’s failure to carry out the covenants, conditions and agreements of this Lease, Landlord may apply the said Security Deposit toward damages as may
be suffered or shall accrue thereafter by reason of the Tenant’s default or breach. In the event of bankruptcy or other debtor-creditor proceedings against Tenant as specified in Article XX, the Security Deposit shall be deemed to be applied
first to the payment of Base Monthly Rent, Additional Rent and other charges due Landlord for the earliest possible periods prior to the filing of such proceedings. The Landlord shall not be obliged to keep the said Security Deposit as a separate
fund, but may mix the same with its own funds. 

  
 21 

 ARTICLE XXVII. MISCELLANEOUS PROVISIONS 

SECTION 27.01 WAIVER. No failure on the part of either party to enforce any covenant or provision of this Lease shall discharge or
invalidate such covenant or provision or affect the right of such party to enforce the same in the event of any subsequent breach. One or more waivers of any covenant or condition by either party shall not be construed as a waiver of a subsequent
breach of the same covenant or condition and the consent to or approval of any subsequent similar act by the other party. No breach of a covenant or condition of this Lease shall be deemed to have been waived by Landlord, unless such waiver be in
writing signed by the party waiving the same. 
 SECTION 27.02 ENTIRE LEASE AGREEMENT. This Lease constitutes the entire
Lease and understanding between the parties hereto and supersedes all prior discussions, understandings and agreements. This Lease may not be altered or amended except by a subsequent written agreement executed by all parties. 

SECTION 27.03 FORCE MAJEURE. Any failure to perform or delay in performance by either party of any obligation under this Lease,
other than Tenant’s obligation to pay rent, shall be excused if such failure or delay is caused by any strike, lockout, governmental restriction or any similar cause beyond the control of the party so falling to perform, to the extent and for
the period that such continues. 
 SECTION 27.04 LOSS AND DAMAGE. The Landlord shall not be responsible or liable to the
Tenant for any loss or damage that may be occasioned by or through the acts or omissions of persons occupying all or any part of the Leased Premises adjacent to or connected with the Leased Premises or any part of the building of which the Leased
Premises are a part, or for any loss or damage resulting to the Tenant or his property from bursting, stoppage or leaking of water, gas sewer or steam pipes or for any damage or loss of property within the Leased Premises from any cause whatsoever.

 SECTION 27.05 ACCORD AND SATISFACTION. No payment by Tenant or receipt by Landlord of a lesser amount than the amount
owing hereunder shall be deemed to be other than on account of the earliest stipulated amount receivable from Tenant, nor shall any endorsement or statement on any check or any letter accompanying any check or payment as rent be deemed an accord and
satisfaction, and Landlord may accept such check or payment without prejudice to Landlord’s right to recover the balance of such rent or receivable or pursue any other remedy available under this Lease or the law of the state where the Leased
Premises are located. 
 SECTION 27.06 NO OPTION. The submission of this Lease for examination does not constitute a
reservation of or option for the Leased Premises and this Lease becomes effective as a lease only upon full execution and delivery thereof by Landlord and Tenant. 
 SECTION 27.07 ANTI-DISCRIMINATION. Tenant herein covenants by and for itself, its heirs, executors, administrators and assigns and all persons claiming under or through it, and this Lease is made
and accepted upon and subject to the following conditions: That there shall be no discrimination against or segregation of any person or group of persons on account of race, sex, marital status, color, creed, national origin or ancestry, in the
leasing, subleasing, assigning, use, occupancy, tenure or enjoyment of the Leased Premises, nor shall the Tenant itself, or any person claiming under or through it, establish or permit any such practice or practices of discrimination or segregation
with reference to the selection, location, number, use or occupancy of tenants, lessees, sublessees, or subtenants in the Leased Premises. 
 SECTION 27.08 SEVERABILITY. If any term, covenant or condition of this Lease or the application thereof to any person or circumstance shall be invalid or unenforceable to any extent, the remainder
of this Lease, or the application of such term, covenant or condition to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby and each term, covenant or condition of this Lease
shall be valid and be enforced to the fullest extent permitted by law. 

  
 22 

 SECTION 27.09 OTHER MISCELLANEOUS PROVISIONS. This instrument shall not be recorded
without the prior written consent of Landlord; however, upon the request of either party hereto, the other party shall join in the execution of a memorandum or “short form” lease for recording purposes which memorandum shall describe the
parties, the Leased Premises, the Rental Term and shall incorporate this Lease by reference, and may include other special provisions. The captions which precede the Sections of this Lease are for convenience only and shall in no way affect the
manner in which any provisions hereof is construed. In the event there is more than one Tenant hereunder, the liability of each shall be joint and several. This instrument shall be governed by and construed in accordance with the laws of the State
wherein the Leased Premises are located. Words of any gender used in this Lease shall be held to include any other gender, and words in the singular number shall be held to include the plural when the sense requires. Time is of the essence of this
Lease and every term, covenant and condition herein contained. 
 SECTION 27.10 REPRESENTATION REGARDING AUTHORITY. The
persons who have executed this Lease Agreement represent and warrant that they are duly authorized to execute this Lease in their individual or representative capacity as indicated. 

SECTION 27.11 DISCLOSURE OF PARTIES. Landlord is a partnership, one or more partners of which is a licensed real estate broker or
agent. 
 SECTION 27.12 TENANT CERTIFICATION. For purposes of compliance with Executive Order 13224 and related
regulations, Landlord and Tenant hereby states, represents and warrants to each other that: 
 (a) Certification. Landlord
and Tenant certify that: 
 (i) They are not acting, directly or indirectly, for or on behalf of any person,
group, entity, or nation named by any Executive Order or the United States Treasury Department as a terrorist, “Specially Designated National and Blocked Person,” or other banned or blocked person, entity, nation, or transaction pursuant
to any law, order, rule, or regulation that is enforced or administered by the Office of Foreign Assets Control; and 
 (ii) They have not executed this Lease, directly or indirectly on behalf of, or instigating or facilitating this Lease, directly or indirectly on behalf of, any such person, group, entity, or nation.

 (b) Indemnification. Tenant and Landlord hereby agrees to defend, indemnify, and hold harmless the other party from
and against any and all claims, damages, losses, risks, liabilities, and expenses (including attorney’s fees and costs) arising from or related to any breach of the foregoing certification. 

ADDITIONAL PROVISIONS: None 
 [Signature Pages to Follow] 
 IN WITNESS WHEREOF, Landlord and
Tenant have executed and delivered this Lease as of the day and year first above written. 
 SIGNATURES: 

 

			
	LANDLORD
	
	SANDY PARK II L.L.C., a Utah limited liability company
		
	By:	 	WOODBURY CORPORATION, a Utah corporation, Its Manager

 
			
		
	        By: 	 	/s/ O Randall Woodbury
		 	O Randall Woodbury, President

 
			
		
	        By: 	 	/s/ Jeffrey K. Woodbury
		 	Jeffrey K. Woodbury, Vice President

  
 23 

 
			
	TENANT
	
	LIFEVANTAGE CORPORATION, a Colorado corporation
		
	By:	 	/s/ Robert M. Urban
	Name:	 	Robert M. Urban
	Title:	 	Chief Operating Officer

 ACKNOWLEDGEMENT OF LANDLORD 
 STATE OF UTAH                ) 
                                   
              : ss. 
 COUNTY OF SALT LAKE ) 

On the 20th day of September, 2012, before me personally appeared O. RANDALL WOODBURY and JEFFREY K. WOODBURY, to me personally
known, who being by me duly sworn did say that they are the President and Vice President of WOODBURY CORPORATION, known to be the Manager of SANDY PARK II L.L.C., a Utah limited liability company, the company that executed the within instrument,
known to me to be the persons who executed the within instrument on behalf of said company therein named, and acknowledged to me that such company executed the within instrument pursuant to its Operating Agreement. 

	
	
	/s/ Angela Dennis
	Notary Public

 ACKNOWLEDGMENT OF TENANT 
 STATE OF UTAH                 ) 
                                   
                  : ss. 
 COUNTY OF SALT LAKE )

 On this 11th day September, 2012, before me personally appeared Robert M. Urban, to me personally known to be the Chief Operating
Officer of LIFEVANTAGE CORPORATION, the corporation that executed the within instrument, known to me to be the person who executed the within instrument on behalf of said corporation therein named, and acknowledged to me that such corporation
executed the within instrument pursuant to its by-laws or a resolution of its board of directors. 
  

	
	/s/ Paula J. Chapman
	Notary Public

  
 24EX-10.31

 EXHIBIT 10.31 

 

					
	

	 		  	Execution Version

 DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT 

This Development Collaboration and License Agreement (“Agreement”) is made and entered into as of the 26th day of July,
2012 (the “Effective Date”) by and between Advanced Liquid Logic, Inc., a Delaware corporation having its principal office at 615 Davis Drive, Suite 800, Morrisville NC, 27560 (“ALL”), and Clinical Micro Sensors,
Inc., d/b/a Genmark Diagnostics, Inc., a Delaware corporation having its principal office at 5964 La Place Court, Carlsbad, CA 92008 (“GenMark”). ALL and GenMark may each be referred to herein individually as a
“Party” and collectively as the “Parties.” 
 WHEREAS, ALL has developed, and owns or controls
certain intellectual property and other rights to, a fluidics technology using the electrowetting effect as a motive force for conducting droplet operations; 
 WHEREAS, GenMark has developed, and owns or controls certain intellectual property and other rights to, technologies related to the electrochemical detection of analytes and to the use of electrochemical
detection in in-vitro diagnostics; and 
 WHEREAS, GenMark wishes to collaborate with ALL in the development of an in-vitro
diagnostic system incorporating ALL’s fluidics technology, and ALL wishes to grant GenMark certain rights and licenses to develop and commercialize such systems on the terms and conditions set forth herein; 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the amount and
sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE 1: DEFINITIONS 

1.1 “Additional Margin” means, for a particular ALL Component supplied by ALL to GenMark under the Supply Agreement in a
particular Calendar Quarter, the amount equal to X/Y; where “X” equals: *** 
 1.2 “Affiliate” means
any Person that, directly or indirectly (through one or more intermediaries) controls, is controlled by, or is under common control with a Party. For purposes of this Section 1.2, “control” means (i) the direct or
indirect ownership of fifty percent (50%) or more of the voting stock or other voting interests or interest in the profits of the Party, or (ii) the ability to otherwise control or direct the decisions of board of directors or equivalent
governing body thereof. 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 1	  

					
	

	 		  	Execution Version

  

 1.3 “ALL Collaboration Inventions” means those Collaboration Inventions
that relate solely to Digital Microfluidics and Collaboration Inventions that are apparatuses or methods that relate solely to Digital Microfluidics. 
 1.4 “ALL Component” means a component of a Consumable Licensed Product supplied by ALL to GenMark pursuant to Section 4.1 or otherwise under this Agreement or the Supply
Agreement, or manufactured by GenMark pursuant to its rights under Section 4.4, as applicable. 
 1.5 “ALL
Confidential Information” means Confidential Information disclosed or provided by, or on behalf of, ALL to GenMark or its designees. 
 1.6 “ALL Development Program Costs” means ALL’s actually incurred (i) direct costs *** ; in each case for activities allocated to ALL as specified in the Development Plan and
satisfactorily completed, which costs shall be determined in accordance with ALL’s auditable, DCAA approved rate structure. 
 1.7 “ALL IP Rights” means all intellectual property rights (including Patents), or rights in confidential or proprietary information (including Technical Information and Materials), owned
or Controlled by ALL as of the Effective Date or during the Term of this Agreement, necessary or useful to make, have made, use, sell, offer for sale, or import Licensed Products in the Field, and including rights to ALL Collaboration Inventions.

 1.8 “Applicable Laws” means all applicable statutes, ordinances, regulations, rules, or orders of any kind
whatsoever of any government or regulatory authority, or court, of competent jurisdiction. 
 1.9 “Business
Day(s)” means any day, other than a Saturday, Sunday or day on which commercial banks located in California are authorized or required by law or regulation to close. 
 1.10 “Calendar Quarter” means a period of three (3) consecutive calendar months ending on each of March 31, June 30, September 30, or December 31.

 1.11 “Calendar Year” means the respective period of a year commencing on January 1 and ending on
December 31. 
 1.12 “Change in Control” of ALL means that during the Term of this Agreement (i) ALL
shall have become an Affiliate of a Person that is a Competitor; and/or (ii) any sale, lease, exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all of the assets of ALL shall have
occurred to a Person that is a Competitor; and/or (iii) the stockholders of ALL shall have approved of a plan or proposal for the liquidation or dissolution of the company, other than one of the events described in (i), (ii) or
(iv) where the 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 2	  

					
	

	 		  	Execution Version

  

 Person is not a Competitor; and/or (iv) any Person that is a Competitor (whether individually or as
part of a group) shall have become the owner, directly or indirectly, beneficially or of record, of shares representing more than fifty percent (50%) of the aggregate ordinary voting power represented by the issued and outstanding voting stock
of ALL. For the purposes of this Section 1.12, “Competitor” means any Person that develops, manufactures, promotes, markets, distributes and/or sells any product used for the diagnosis, prognosis, monitoring, screening
or predicting a disease or condition in a human, or selecting a therapeutic or prophylactic regimen, which product either (a) detects a DNA, RNA or other nucleotide sequence analyte, excluding detection of the foregoing utilizing Sequencing, or
(b) utilizes Electrochemical Detection. 
 1.13 “CEA Agreement” means that certain License Agreement,
dated September 9, 2011, between Advanced Liquid Logic France S.A.S and Commissariat a Penergie atomique et aux energies alternatives (“CEA”), including the exhibits or appendices thereto, existing as of the Effective Date.

 1.14 “CEA IP” means ALL IP Rights Controlled by ALL pursuant to the intercompany agreement between ALL and
Advanced Liquid Logic France S.A.S., an Affiliate of ALL, dated October 1, 2011. 
 1.15 “Collaboration Enabled
Inventions” means all Technical Information and Materials (whether or not patentable) that either: (i) if embodying patentable subject matter, are first conceived (as the preceding terms are defined in the context of U.S. Patent laws),
or (ii) if not embodying patentable subject matter, are otherwise first created; in each case (a) as a direct result of GenMark’s activities, during the Development Term and for the period two (2) years following expiration or
termination of the Development Term (including expiration or termination pursuant to Section 10.4), to develop Consumable Licensed Products or Instrument Licensed Products (including activities performed by a Third Party on a
GenMark’s behalf), (b) the subject matter of which is either Digital Microfluidics or Digital Microfluidics Related, and (c) that are not Collaboration Inventions. 

1.16 “Collaboration Enabled IP Rights” means all intellectual property rights (including Patents), or rights in
confidential or proprietary information (including Technical Information and Materials), owned or Controlled by GenMark during the Term of this Agreement in and to Collaboration Enabled Inventions. 

1.17 “Collaboration Inventions” means all Technical Information and Materials (whether or not patentable) (a) that
either (i) if embodying patentable subject matter, are first conceived (as the preceding terms are defined in the context of U.S. Patent laws), or (ii) if not embodying patentable subject matter, are otherwise created; in each case either
as a direct result of activities undertaken by the Parties under the Development Plan; or (b) that are supported by ALL Development Program Costs; in each case including activities undertaken by the Parties and including the participation of
one or more Third Parties. 
 1.18 “Commercially Reasonable Efforts” means the exercise of such efforts and
commitment of such resources by a Party as would be expended on, or committed by such Party to, a comparable development or commercialization program of a similar scope and at a similar 

  

					
	Development Collaboration and License Agreement	  	 	Page 3	  

					
	

	 		  	Execution Version

  

 
stage in development or product lifecycle, comparable market potential and market size, profit margin, competitive landscape, and risk profile, probability of technical success, technical and
regulatory profile and patent protection, in a particular geographic region. 
 1.19 “Complex” means a complex
comprising a capture ligand coupled to an electrode surface, a target analyte, and an Electrochemical Label. 
 1.20
“Confidential Information” means (i) all information and materials (of whatever kind and in whatever form or medium) disclosed by or on behalf of a Party to the other Party (or its designee) in connection with this Agreement,
including any Technical Information and Materials, whether prior to or during the term of this Agreement and whether provided orally, electronically, visually, or in writing; (ii) all copies of the information and materials described in
(i) above; and (iii) the existence and each of the terms and conditions of this Agreement. “Confidential Information” shall not include, to the extent a Party can demonstrate, through its contemporaneous written records,
information and materials (a) known to the receiving Party, or in the public domain, at the time of its receipt by a Party, or which thereafter becomes part of the public domain other than by virtue of a breach of this Agreement or the
obligations of confidentiality under this Agreement; (b) received without an obligation of confidentiality from a Third Party having the right to disclose without restrictions on such information; (c) independently developed by the
receiving Party without use of or reference to Confidential Information disclosed by the other Party; and (d) released from the restrictions set forth in this Agreement by the express prior written consent of the disclosing Party. 

1.21 “Consumable Licensed Products” means the single use, disposable components of a Licensed Product, the manufacture,
use, sale, offer for sale, or importation of which components, would (but for a license from ALL under this Agreement) infringe a Valid Claim of a Patent within the ALL IP Rights. For clarity, a Consumable Licensed Product may include one or more
ALL Components. 
 1.22 “Control(s)” or “Controlled” means the possession by a Party, as of
the Effective Date or during the term of this Agreement, of (i) with respect to materials, data or information, the right to physical possession of those items, with the right to provide them to Third Parties; and (ii) with respect to
intellectual property rights, rights sufficient to grant the applicable license or sublicense under this Agreement, without violating the terms of any agreement with any Third Party existing prior to the Effective Date. 

1.23 “Covers” or “Covered by.” or the like, with reference to a particular Licensed Product means that
the use, sale, offer for sale or import of such Licensed Product would, but for a license granted under this Agreement, infringe a Valid Claim of the relevant Patent in the country in which, and on the date which, the relevant Licensed Product is
used, sold, offered for sale or imported; provided that with respect to use, sale, offer for sale or import of a Licensed Product in a country other than a Major Country, such use, sale, offer for sale or import shall also be deemed
“Covered” by a Valid Claim of a Patent in such country for purposes of the any royalty obligation to ALL under Article 6 or, if applicable, Section 4.5, or the determination of Additional Margin if the use, sale, offer
for sale or import of such Licensed Product would be Covered by a Valid Claim of a relevant Patent in each and every Major County on the date that such Licensed Product is used, sold, offered for sale or imported, if such activity occurred in a
Major Country. 

  

					
	Development Collaboration and License Agreement	  	 	Page 4	  

					
	

	 		  	Execution Version

  

 1.24 “Development Plan” means the written research plan for the
Development Program, attached hereto at Schedule A. The Development Plan may be amended or modified from time to time by the Joint Development Committee. 
 1.25 “Development Program” means the program of activities the Parties engage in under this Agreement, which program is set forth on the Development Plan, and including all activities
supported by the funding provided by GenMark under Sections 2.4 and 6.3. 
 1.26 “Development Term”
means the period of time during which each Party will undertake activities in the Development Program or on the Development Plan. 
 1.27 “Diagnostic Testing” means testing for the purpose of diagnosis, prognosis, monitoring, screening or predicting a disease or condition in a human, or selecting a therapeutic or
prophylactic regimen; excluding screening of newborn infants for metabolic or other disorders in fields other than in the Molecular Analyte Field using GenMark e-Detection. 
 1.28 “Digital Microfluidics” means the control of the movement, including the transport, splitting, dispensing, merging or deforming, of droplets by electrical fields. 

1.29 “Digital Microfluidics Related” means (i) design of Digital Microfluidics cartridges; (ii) manufacturing
of Digital Microfluidics aspects of cartridges; and (iii) electronics and/or software for controlling Digital Microfluidics. 
 1.30 “Direct Manufacturing Cost” of an ALL Component means the actual, direct cost per unit, for clarity excluding overhead, of manufacture of such ALL Component, as determined in
accordance with GAAP and ALL’s auditable, DCAA approved rate structure. 
 1.31 “Direct Manufacturing Cost
Cap” means, *** 
 *** 
 *** 
 *** 

 

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 5	  

					
	

	 		  	Execution Version

  

 1.32 “*** Agreement” means that certain *** License Agreement between
ALL and *** , including the exhibits or appendices thereto, existing as of the Effective Date. 
 1.33 “*** IP”
means the ALL IP Rights (including Patents) Controlled by ALL pursuant to the *** Agreement. 
 1.34 “Effective
Date” has the meaning set forth in the introductory paragraph of the Agreement. 
 1.35 “Electrochemical
Detection” means the use of at least two electrodes to apply potential and measure current produced by a chemical reaction occurring in a liquid in contact with the electrodes. For the sake of clarity, “Electrochemical Detection”
excludes detection (i) of conductivity, impedance or capacitance of a droplet, a portion of a droplet, or the contents of a droplet; (ii) by electrochemilumenescence; and (iii) by optical means. 

1.36 “Electrochemical Label” means moieties that function in a Complex to produce an electrical signal (detected by an
electrode) by oxidation or reduction of the moiety, including metal complexes of iron, ruthenium, and osmium. Except when used in Section 5.1.3, “Electrochemical Label” shall exclude enzymatic labels and labels that function by
releasing hydrogen ions. 
 1.37 “FDA” means the U.S. Food and Drug Administration or corresponding
governmental authority in another country, or any successor thereto. 
 1.38 “Field” means the Protein Analyte
Field and Molecular Analyte Field, and subject to exercise of the Option in accordance with Section 5.2. the Other Analyte Field. 
 1.39 “Filing” or “Filed” with respect to an application for Marketing Approval means that such application has been filed with the appropriate Regulatory Authority and,
consistent with the current practices of such Regulatory Authority, the Regulatory Authority has made a threshold determination that the application for Marketing Approval is sufficiently complete to permit a substantive review. 

1.40 “First Commercial Sale” means, with respect to a given Licensed Product in a particular country, the first bona
fide sale of such Licensed Product in such country, by or under authority of GenMark or its Sublicensee or distributor, which sale is included in the calculation of Net Sales. 
 1.41 “GAAP” shall mean United States generally accepted accounting principles, consistently applied. 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 6	  

					
	

	 		  	Execution Version

  

 1.42 “GenMark Collaboration Inventions” means those Collaboration
Inventions that relate solely to Electrochemical Detection and Collaboration Inventions that are apparatuses or methods that relate solely to Electrochemical Detection. 
 1.43 “GenMark Confidential Information” means Confidential Information disclosed or provided by, or on behalf of, GenMark to ALL or its designees. 

1.44 “GenMark e-Detection” means the detection of an analyte based on a Complex where the Electrochemical Label is
detected using Electrochemical Detection. 
 1.45 “GenMark IP Rights” means all intellectual property rights
(including Patents), or rights in confidential or proprietary information (including Technical Information and Materials), owned or Controlled by GenMark as of the Effective Date or during the Term of this Agreement, including rights to GenMark
Collaboration Inventions, necessary for ALL to undertake the activities allocated to ALL in the Development Plan. 
 1.46
“Good Manufacturing Practices” or “GMP” means the Applicable Laws governing, and guidelines issued by any Regulatory Authority applicable to, the manufacture, labeling, packaging, handling, storage, and transport of
Licensed Products, including those pursuant to the United States Federal Food Drug & Cosmetic Act and the regulations found in Title 21 of the U.S. Code of Federal Regulations (including Part 820), as are in effect at the Effective Date or
as may subsequently be modified or supplemented, or any foreign equivalents thereof. 
 1.47 “Instrument Licensed
Products” means the parts or components of a Licensed Product other than Consumable Licensed Products, the manufacture, use, sale, offer for sale, or importation of which parts or components, would (but for a license from ALL under this
Agreement) infringe a Valid Claim of a Patent within the ALL IP Rights. 
 1.48 “Joint Collaboration
Inventions” means Collaborations Inventions other than ALL Collaboration Inventions and GenMark Collaboration Inventions. 
 1.49 “Joint Collaboration IP Rights” means all intellectual property rights (including Patents), or rights in confidential or proprietary information (including Technical Information and
Materials), in and to Joint Collaboration Inventions. 
 1.50 “Joint Development Committee” or
“JDC” is defined in Section 2.2.1. 
 1.51 “Licensed Product(s)” means a product
for use in Diagnostic Testing, including Instrument Licensed Products and Consumable Licensed Products. 
 1.52 “Major
County” means the United States, Canada, the United Kingdom, Germany, France, Spain, Italy, Republic of Korea, Japan, India and China. 
 1.53 “Molecular Analyte Field” means in-vitro Diagnostic Testing of samples from (or derived from) human subjects using Electrochemical Detection of a DNA, RNA or other nucleotide
sequence analyte, excluding testing utilizing Sequencing. 

  

					
	Development Collaboration and License Agreement	  	 	Page 7	  

					
	

	 		  	Execution Version

  

 1.54 “Net Capital Sales” means a Net Sale of an Instrument Licensed
Product resulting in the transfer of title of the Instrument Licensed Product to a Third Party. 
 1.55 “Net
Sales” means the gross amounts invoiced for sales of Licensed Products (including, if applicable, GenMark Manufactured Consumables) by GenMark, its Affiliates and its Sublicensees (in final form for end use), less the following deductions
from such invoiced amounts which are actually incurred or accrued: 
  

	 	(a)	credits or allowances granted for damaged, outdated, returned, rejected or recalled Licensed Products, and uncollectible amounts on previously sold Licensed Products
and retroactive price reductions; 

  

	 	(b)	normal and customary trade, cash and quantity discounts or rebates; 

  

	 	(c)	taxes, duties and any other governmental charges or levies imposed upon or measured by the import, export, use, manufacture or sale of Licensed Products, as adjusted
for rebates and refunds, as applicable; 

  

	 	(d)	chargebacks and rebates, including those granted to managed health care organizations, wholesalers, buying groups, retailers or to federal, state/provincial, local and
other governments, their agencies and purchasers and reimbursers; 

  

	 	(e)	freight, insurance, data, administrative, and other charges or fees related to the handling and distribution of Licensed Products or services provided in connection
with the handling or distribution of Licensed Products (to the extent not paid by the Third Party customer); 

  

	 	(f)	credits and allowances made for wastage replacement; and 

  

	 	(g)	reasonable indigent or similar programs. 

 All of the foregoing elements of Net Sales calculations shall be determined in accordance with GAAP. 
 Sales between or among a Party and its Affiliates shall be excluded from the computation of Net Sales, but Net Sales shall include the first sales to Third Parties by any such Affiliates. The supply of
Licensed Products by or on behalf of GenMark as samples, for use in non-clinical or clinical studies conducted by or on behalf of GenMark, or for use in any tests or studies conducted by or on behalf of GenMark reasonably necessary to comply with
any Applicable Law or request by a regulatory or governmental authority shall not be included within the computation of Net Sales. 
 In the event a Consumable Licensed Product is sold as a combination of products that are Covered by a Valid Claim of a Patent within the ALL IP Rights and at least one other product that is not Covered by
a Valid Claim of a Patent within the ALL IP Rights (as used in this definition of Net Sales, a “Combination”), the gross amount invoiced for such Licensed Product shall be calculated by multiplying the gross amount invoiced for such
Combination by the fraction A/(A+B), where “A” is the gross amount invoiced for such Licensed Product when sold separately and “B” is the gross amount invoiced for such other products when sold separately. 

  

					
	Development Collaboration and License Agreement	  	 	Page 8	  

					
	

	 		  	Execution Version

  

 In the event that such separate sales of products in a Combination were not made or
performed during the applicable Calendar Quarter, then the gross amount invoiced for a Licensed Product that is sold as part of a Combination shall be calculated by multiplying Net Sales of the Combination by the fraction C/(C+D), where
“C” is the fully allocated cost of the Licensed Product and “D” is the fully allocated cost of the products in the Combination that are not Covered by a Valid Claim of a Patent within the ALL IP Rights 

The Parties agree that any allocation of revenue from the sale or other disposition of Combination pursuant to this
Section 1.55 shall be done in good faith, and shall take into consideration revenue recognition guidance under GAAP which is applicable to multiple- deliverable revenue arrangements. 

1.56 “Other Analyte Field” means in-vitro Diagnostic Testing of samples from (or derived from) human subjects using
Genmark e-Detection of an analytes other than: (i) proteins and/or peptides and (ii) DNA, RNA or other nucleotide sequences. 
 1.57 “Patent(s)” means a patent or a patent application, including any additions, divisions, continuations, continuations-in-part, pipeline protection, invention certificates,
substitutions, reissues, reexaminations, extensions, registrations, patent term extensions, supplementary protection certificates and renewals of any of the above. 
 1.58 “Person” means any person or entity, including any individual, trustee, corporation, partnership, trust, unincorporated organization, limited liability company, business association,
firm, joint venture or governmental agency or authority. 
 1.59 “Protein Analyte Field” means in-vitro
Diagnostic Testing of samples from (or derived from) human subjects using GenMark e-Detection of a protein and/or peptide analyte. 
 1.60 “Regulatory Authority” means any national (e.g., the FDA), supra-national (e.g., the EMEA), regional, state or local regulatory agency, department, bureau, commission,
council or other governmental entity, in any jurisdiction of the world, involved in the granting of Marketing Approval. 
 1.61
“Sequencing” means a method of determining the order of bases (in each case, including modified bases) of a target nucleic acid strand or segment by: (a) serially determining each base or subset of bases along a strand or
segment (e.g., “sequencing-by-synthesis”, single-molecule sequencing); (b) hybridization, wherein at least one thousand (1000) distinct probes are used to determine such nucleotide sequence; (c) separating fragments
based on size (e.g., “Sanger sequencing”); (d) any method that determines the order of no less than fifty (50) contiguous bases; or (e) any method that requires no prior knowledge of the expected order of bases for
the target nucleic acid. 
 1.62 “Technical Information and Material” means all compositions of matter,
techniques and data and other know-how and technical information, including inventions 

  

					
	Development Collaboration and License Agreement	  	 	Page 9	  

					
	

	 		  	Execution Version

  

 (whether or not patentable), improvements and developments, practices, methods, concepts, know-how,
trade secrets, documents, computer data, computer code, apparatus, clinical and regulatory strategies, test data, analytical and quality control data, formulation, manufacturing, patent data or descriptions, development information, drawings,
specifications, designs, plans, proposals and technical data and manuals and all other proprietary information. 
 1.63
“Territory” means the entire world. 
 1.64 “Third Party” means a Person that is not a Party
to this Agreement or an Affiliate of a Party to this Agreement. 
 1.65 “*** Agreement” means that certain ***
Exclusive License Agreement between the *** and ***, including the exhibits or appendices thereto, existing as of the Effective Date. 
 1.66 “*** IP” means the ALL IP Rights Controlled by ALL pursuant tothe *** Agreement. 
 1.67 “Valid Claim” means a claim of an issued and unexpired Patent that has not been (i) disclaimed, revoked, abandoned, or dedicated to the public; (ii) held unenforceable or
invalid by a decision of a court, governmental agency or other authority of competent jurisdiction, which decision is unappealable or unappealed within the time allowed for appeal, or (iii) admitted to be invalid or unenforceable through
reissue, reexamination, disclaimer or otherwise. 
 ARTICLE 2: DEVELOPMENT PROGRAM 

2.1 Development Program Overview and Responsibilities. Under this Agreement, the Parties are establishing a collaborative
development program in which the Parties will work together, during the Development Term, in accordance with the Development Plan, to design and validate products utilizing Digital Microfluidics and Electrochemical Detection for use in Diagnostics
Testing (“Development Program”). Each Party shall use diligent efforts to perform its responsibilities under the Development Plan and shall cooperate with and provide reasonable support to the other Party in such other Party’s
performance of its responsibilities thereunder. 
 2.2 Joint Development Committee. 

2.2.1 The JDC. Within ten (10) Business Days after the Effective Date, the Parties shall establish a committee to monitor the
Development Program, and to plan and coordinate the activities under the Development Plan (“Joint Development Committee” or “JDC”). The JDC will be composed of no more than three (3) representatives designated
by each Party (and the Parties need not have the same number of representatives). Representatives must be appropriate for the tasks then being undertaken, in terms of their seniority, availability, function in their respective organizations,
training and experience. Each Party shall designate one of its representatives as its primary JDC contact for JDC matters (such Party’s “JDC Co- Chair”). From time to time, the JDC may establish subcommittees to oversee
particular projects or activities; those subcommittees will be constituted and operate as the JDC determines. The JDC shall meet during the Development Term; thereafter, the JDC shall cease operations and perform no further functions under this
Agreement. 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 10	  

					
	

	 		  	Execution Version

  

 2.2.2 Meetings. Once established, the Joint Development Committee shall meet at
least once each Calendar Quarter (unless otherwise agreed by the Parties) during its term of operations, as set forth in Section 2.2.1, and shall meet at such other times as deemed appropriate by the JDC. The JDC may meet in person or
via teleconference, video conference or the like, provided that at least one (1) meeting per Calendar Year shall be held in person, unless otherwise agreed by the Parties. Each Party shall bear the expense of its respective
representatives’ participation in JDC meetings. If a Party’s representative is unable to attend a given meeting, such Party may designate an alternate to attend such meeting and perform the functions of such representative. Each Party may,
with the prior written consent of the other Party, invite a reasonable number of non-voting employees, consultants or scientific advisors to attend JDC meetings. Those invitees must be bound by appropriate confidentiality obligations. 

2.2.3 Responsibilities of JDC. Subject to Section 2.2.4, the Joint Development Committee shall perform the following
functions: 
  

	 	(i)	review and amend the Development Plan, as needed; 

  

	 	(ii)	review and approve the allocation of resources and efforts for the Development Program; 

 

	 	(iii)	evaluate the progress of the Development Program; 

  

	 	(iv)	establish and oversee a process by which each Party keeps the other Party informed of design or manufacturing changes, feedback from lead users (if any), or events
which may affect work being performed under the Development Plan or GenMark’s development of Licensed Products; 

  

	 	(v)	coordinate, and be the primary conduit for, the transfer of Technical Information and Materials between the Parties during the Development Term; and

  

	 	(vi)	perform such other functions referred to in the Development Plan, and as appropriate to further the purposes of the Development Program, or as otherwise specified in
this Agreement or agreed to by the Parties. 

 2.2.4 Decision-Making Authority. The Joint Development
Committee will attempt to make decisions by consensus. If the JDC cannot reach consensus, within three (3) Business Days after it has attempted to reach consensus, the matter shall be referred to the respective Chief Executive Officers of the
Parties (or their respective senior level officer designees) (the “Executive Officers”). If the Executive Officers cannot reach a mutually acceptable decision within three (3) Business Days after the matter was referred to them, then
GenMark shall have final decision making authority; provided that mutual written consent of the Parties is required for any decisions that would result in a material change to the scope of activities assigned to ALL under a Development Plan or the
time for completion an activity 

  

					
	Development Collaboration and License Agreement	  	 	Page 11	  

					
	

	 		  	Execution Version

  

 
assigned to ALL under a Development Plan, including changes that would require ALL to: (i) violate any obligation or agreement it may have with a Third Party, or (ii) incur any costs
cumulatively exceeding three thousand dollars ($3,000) not reimbursable by GenMark. By way of example, the JDC shall not obligate ALL to perform activities under the Development Plan beyond those that could reasonably be expected to be performed by
the number of FTEs funded by GenMark during the relevant time period. The JDC has no authority to amend, or to waive compliance with, any provisions of this Agreement, or to make any decision outside the scope and purpose of this Agreement. For
clarity, the dispute resolution provisions of Article 14 shall not apply to decisions allocated to the JDC, except with respect to disputes as to the JDCs authority to make a disputed decision. 

2.2.5 Minutes; Other Documentation of Decisions. The Joint Development Committee shall keep minutes of its meetings that record in
writing all decisions made, action items assigned or completed and other appropriate matters. The responsibility for keeping meeting minutes shall alternate between the Parties, beginning with GenMark. Meeting minutes shall be sent to both Parties
promptly after a meeting for review, comment and approval by each Party. A decision that may be made at a JDC meeting may also be made without a meeting if such decision is agreed to in writing (including by email) by each Party’s JDC Co-Chair
(or its designee), provided that each Party’s writing clearly indicates that such decision is a formal decision by such Party’s JDC representatives. Any modifications to the Development Plan that are approved by the JDC shall constitute an
amendment to the Development Plan. 
 2.3 Subcontracting. ALL shall not subcontract or outsource any work or any of its
activities under the Development Plan to a Third Party without GenMark’s prior written consent. Provided that ALL has obtained the required consent, any subcontractor or Third Party to which work is outsourced must: (a) be under ALL’s
direct supervision and control; (b) have entered into a written agreement with ALL that either has been approved by GenMark in advance or includes terms and conditions protecting and limiting use and disclosure of Confidential Information,
Technical Information and Materials to the same extent as under this Agreement, and requiring all such individuals to assign to ALL all right, title and interest in and to any intellectual property (and intellectual property rights) created or
discovered. ALL is responsible for compliance by any subcontractor or Third Party to which work is outsourced with the terms and conditions of this Agreement as if such subcontractor or Third Party was ALL’s employees. 

2.4 Development Program Costs. As consideration due ALL for the performance of activities allocated to ALL in the Development Plan
and satisfactorily completed, GenMark shall, in accordance with Section 6.3, reimburse ALL for the ALL Development Program Costs incurred by ALL in the performance of such activities. Other than the reimbursement of ALL Development
Program Costs, ALL shall bear costs incurred by it in undertaking and carrying out the Development Program and performing under the Development Plan. 

  

					
	Development Collaboration and License Agreement	  	 	Page 12	  

					
	

	 		  	Execution Version

  

 ARTICLE 3: DEVELOPMENT AND COMMERCIALIZATION EFFORTS 

3.1 Development and Commercialization Responsibilities. 
 3.1.1 GenMark Rights. Except for those activities allocated to ALL in the Development Plan and in the Supply Agreement, as between the Parties, GenMark (and, if applicable, GenMark Licensees)
shall, subject to the rights and licenses granted to GenMark by ALL under this Agreement, have the right and sole responsibility for (including costs and expenses), and control over, all development and commercialization activities, including
without limitation all regulatory activities, with respect to any Licensed Products. 
 3.1.2 ALL Cooperation. ALL shall,
and shall cause its employees, contractors and agents to, cooperate with and provide reasonable support and assistance to GenMark in its conduct of any activities in the development, obtaining and maintaining regulatory clearances and approvals,
manufacturing (subject to Article 4). and commercialization, of Licensed Products. 
 3.2 GenMark Diligence.

 3.2.1 General Diligence Requirement. Subject to ALL’s obligations under Section 2.1, GenMark shall use
Commercially Reasonable Efforts to develop, seek regulatory approval for, and commercialize at least one Licensed Product. Activities by GenMark’s Affiliates, distributors, and Sublicensees related to the development, seeking of regulatory
approval for, and commercialization of a Licensed Product will be considered as GenMark’s activities under this Agreement for purposes of determining whether GenMark has complied with its obligations under this Section 3.2.

 3.2.2 Conversion to Non-Exclusive License. If the First Commercial Sale of a Licensed Product has
not occurred by the fifth (5th) anniversary of the
Effective Date, except to the extent due the breach of this Agreement or the Supply Agreement by ALL, then ALL may, within forty five (45) days of such fifth (5th) anniversary of the Effective Date, provide GenMark written notice (“Conversion Notice”) of its
intention to convert the exclusive licenses granted to GenMark in Sections 5.1.1. 5.1.2 and 5.2 to non-exclusive licenses. GenMark shall have to option to maintain the exclusivity of the licenses granted to GenMark in Sections 5.1.1. 5.1.2
and 5.2 by, within thirty (30) days of GenMark’s receipt of a Conversion Notice (“Extended Exclusivity Option Period”), providing notice thereof to ALL (“Exclusivity Extension Exercise”) and paying
ALL            ***            (“Exclusivity Extension Fee”). If ALL has timely provided a Conversion Notice and GenMark
has not, within the Extended Exclusivity Option Period, provided ALL with an Exclusivity Extension Exercise notice and paid the Exclusivity Extension Fee, the licenses granted to GenMark in Sections 5.1.1. 5.1.2 and 5.2 shall become
non-exclusive. If ALL has timely provided a Conversion Notice and GenMark has timely provided ALL with an Exclusivity Extension Exercise notice and paid the Exclusivity Extension Fee, the licenses granted to GenMark in Sections 5.1.1. 5.1.2 and
5.2 shall remain exclusive, provided that the First Commercial Sale of a Licensed Product occurs by the seventh
(7th) anniversary of the Effective Date. If the First
Commercial Sale of a Licensed Product has not occurred by the seventh (7th) anniversary of the Effective Date, except to the extent due the 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 13	  

					
	

	 		  	Execution Version

  

 breach of this Agreement or the Supply Agreement by ALL, then ALL shall have the right to terminate this
Agreement pursuant to Section 10.2.1. If paid, the Exclusivity Extension Fee shall be fully creditable against any future payment due to ALL pursuant to Section 6.4. 

3.3 Reports. Following the Development Term, and until the First Commercial Sale of a Licensed Product, GenMark shall, if
requested by ALL, provide to ALL a summary of GenMark’s progress on the development of, and seeking regulatory approval for, Licensed Products. Such a request shall not be made more than once per Calendar Year. All reports provided to ALL under
this Section 3.3 are GenMark Confidential Information. 
 ARTICLE 4: MANUFACTURE AND SUPPLY 

4.1 Supply of ALL Components. During the Development Term, and following the Development Term provided that the Parties are in the
process of negotiating a Supply Agreement pursuant to Section 4.2 or have executed the Supply Agreement, ALL shall be the exclusive supplier of those components of a Consumable Licensed Product that incorporate ALL’s proprietary
Digital Microfluidics technology or the manufacture of which requires the application of ALL’s proprietary manufacturing technology or techniques, in either case provided that upon execution of the Supply Agreement: (i) ALL is able to, and
does, manufacture and supply sufficient quantities of such ALL Components to meet GenMark’s reasonably forecasted needs and product specifications; (ii) such ALL Components are manufactured and supplied in accordance with and to the extent
required by (x) the Applicable Laws (including to the extent required by the jurisdiction in which the facility is located or where the Licensed Product shall be used or sold) pertaining to the manufacture, supply, and clearance and/or approval
of medical diagnostics devices in the relevant countries and jurisdictions for use with or in a Licensed Product to be manufactured, distributed or marketed by GenMark, its Affiliates and Sublicensees and (y) the Applicable Laws pertaining to
the manufacture, supply, and clearance and/or approval of medical diagnostics devices in the relevant countries and jurisdictions applicable to the qualification and/or registration of ALL as a manufacturer and supplier of ALL Components for use
with or in a Licensed Product to be manufactured, distributed or marketed by GenMark, its Affiliates and Sublicensees; and (iii) there has not been a Change of Control of ALL. 

4.2 Supply Agreement. 
 4.2.1 Generally. The Parties shall enter into a separate agreement or agreements governing the roles and responsibilities of the Parties in the manufacture, supply, testing, release and storage of
ALL Components (the “Supply Agreement”). The Supply Agreement shall contain customary terms and conditions contained in similar agreements of the type, including those related to forecasting, ordering, shipment and delivery,
representations, warranties and indemnities concerning the quality of product manufactured and supplied, and manufacturing facility audit and inspection rights. The Parties shall, at least ninety (90) days prior to the anticipated expiration of
the Development Term, initiate negotiations of the Supply Agreement. 
 4.2.2 Benchmarking of Direct Manufacturing Costs.
The Supply Agreement shall set forth a process for the external benchmarking required to determine the Direct 

  

					
	Development Collaboration and License Agreement	  	 	Page 14	  

					
	

	 		  	Execution Version

  

 
Manufacturing Cost Cap. Such process shall be initially conducted six (6) months following the First Commercial Sale of a Consumable Licensed Product or Instrument Licensed Product
incorporating an ALL Component to determine the initial Direct Manufacturing Cost Cap, and thereafter no more than once per calendar year promptly following each anniversary of the execution of the Supply Agreement. 

4.2.3 Arbitration. 
 (a) If, despite the diligent and good faith efforts of the Parties, the Parties are unable to prepare and execute the Supply Agreement within a period of at least ninety (90) days from the written
request of either Party to initiate negotiations of the Supply Agreement in accordance with Section 4.2.1, then either Party may submit the matter to final and binding arbitration under the auspices of the American Arbitration
Association (“AAA”). Any such arbitration shall be conducted in a mutually convenient location agreed to by the Parties pursuant to the then-current commercial arbitration rules of the AAA, as modified herein. Such arbitration shall
be conducted in the English language. The arbitration tribunal shall consist of a single arbitrator who is an independent expert in manufacturing and supply of in-vitro diagnostic products, mutually acceptable to the Parties. If the Parties are
unable to agree on an arbitrator, the arbitrator shall be an independent expert as described in the preceding sentence selected by the chief executive of the office of the AAA nearest to the location of the arbitration. 

(b) Any such arbitration hereunder shall be a “baseball” type arbitration. Accordingly, notwithstanding the commercial
arbitration rules of the AAA, each Party shall provide to the arbitrator, and the other Party, its proposed version of the Supply Agreement. Each Party may submit a revised version of its proposed Supply Agreement to the arbitrator and the other
Party within thirty (30) days after receiving the other Party’s initial proposal. If so requested by the arbitrator, each Party shall make oral submissions to the arbitrator based on such Party’s proposal; provided that other Party
shall have the right to be present during any such oral submissions. The arbitrator shall select one Party’s proposed Supply Agreement as his or her decision, and shall not have the authority to render any substantive decision other than to
select the proposal submitted by either GenMark or ALL (as initially submitted, or as revised in accordance with the foregoing, as applicable). The Parties shall use diligent efforts to complete any arbitration within sixty (60) days following
a request by a Party for such arbitration. 
 (c) The administrative charges, arbitrator’s fees, and related expenses of
any arbitration shall be shared equally by the Parties, but each Party shall be responsible for its own expenses in connection with such arbitration (including its own attorneys’ fees). 

(d) The decision of the arbitrator shall be the binding remedy between the Parties regarding the dispute presented to the arbitrator.
Any decision of the arbitrator may be entered in a court of competent jurisdiction for judicial recognition of the decision and an order of enforcement. 
 4.3 Transfer Price. The price of ALL Components supplied by ALL to GenMark under the Supply Agreement shall be as set forth in Section 6.8. 

  

					
	Development Collaboration and License Agreement	  	 	Page 15	  

					
	

	 		  	Execution Version

  

 4.4 Transition of Manufacturing Know-How. In the event that (a) either
condition (i) or (ii) of Section 4.1 to ALL’s right to exclusively supply ALL Components is not met and ALL fails to cure such condition(s) within sixty (60) days of receiving written notice thereof from GenMark,
(b) there has been a Change of Control of ALL, or (c) there is an Uncured Material Breach by ALL of Section 2.1; then, in each case, at GenMark’s request, such request to be made in writing within sixty (60) days of
each occurrence of ALL’s failure to cure, ALL shall promptly provide and transfer to GenMark (or GenMark’s designee), all Technical Information and Materials used by ALL (and its Affiliates and Third Party contract manufacturers) in
connection with the manufacture of Licensed Products to enable GenMark, either itself or through or with an Affiliate, Sublicensee or permitted Third Party, to manufacture the Licensed Products. ALL shall consult, cooperate with and assist GenMark
(or GenMark’s designee) in connection with the manufacturing of Licensed Products pursuant to this Section 4.4, if and to the extent reasonably requested by GenMark. In addition, upon request by GenMark, ALL shall continue to
manufacture and supply to GenMark, for a reasonable transition period to be agreed to by the Parties, ALL Components. If GenMark invokes its rights under this Section pursuant to (a) or (c) of this Section, GenMark shall reimburse ALL for
*** of the direct costs incurred by ALL for activities undertaken by ALL at GenMark’s request in accordance with this Section 4.4. If GenMark invokes its rights pursuant to (b) of this Section, GenMark shall reimburse ALL for
*** of the direct costs incurred by ALL for activities undertaken by ALL at GenMark’s request in accordance with this Section 4.4, and shall, to the extent requested in writing by ALL, (i) purchase from ALL any equipment owned
by ALL that is necessary to manufacture ALL Components supplied to GenMark and is more than fifty percent (50%) devoted to the manufacture of ALL Components for GenMark and (ii) assume any agreements between ALL and a Third Party for the
supply of materials necessary to manufacture ALL Components and one hundred percent (100%) devoted to materials used to manufacture ALL Components for GenMark, if permitted by such agreement without penalty or material change to the terms of
such agreement. The transition of manufacturing know-how pursuant to this Section 4.4 does not imply any modification of the licenses granted to GenMark in Article 5 or constitute an assignment to GenMark of ownership of any ALL
IP Rights or any other intellectual property rights of ALL. For clarity, a dispute or disagreement as to whether either condition (i) or (ii) of Section 4.1 to ALL’s right to exclusively supply ALL Components has not been
met, or whether ALL has timely cured the same, shall be subject to Article 14. 
 4.5 Royalty for Manufacture of ALL
Components. Provided that GenMark has obtained the right to manufacture (or have manufactured) ALL Components pursuant to Section 4.1, then in each Calendar Quarter during the Term of this Agreement in which GenMark records Net Sales
of a Consumable Licensed Product that contains ALL Components that are manufactured by GenMark or otherwise not manufactured and supplied pursuant to the Supply Agreement (“GenMark Manufactured Consumables”), and subject to and in
accordance with the terms and conditions of this Agreement, GenMark shall pay to ALL an amount equal to: (i) *** of GenMark Manufactured Consumables during such Calendar Quarter, if GenMark has obtained the right to manufacture (or have
manufactured) ALL Components pursuant to Section 4.1 other than solely due to a Change of Control of ALL; or (ii) *** of GenMark Manufactured Consumables during such Calendar Quarter, if GenMark has obtained the right to manufacture
(or have manufactured) ALL Components pursuant to Section 4.1 solely due to a Change of Control of ALL. 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 16	  

					
	

	 		  	Execution Version

  

 ARTICLE 5: LICENSE GRANTS; OPTIONS 

5.1 Licenses to GenMark. 
 5.1.1 Exclusive License in GenMark e-Detection. ALL hereby grants to GenMark, and GenMark hereby accepts, an exclusive (even as to ALL, but subject to the license back to ALL in
Section 5.2) right and license, under the under the ALL IP Rights and ALL’s interest in Joint Collaboration IP Rights, to make, have made, use, sell, offer for sale, and import in the Territory those Licensed Products utilizing
GenMark e-Detection for use in the Field. 
 5.1.2 Exclusive License in Molecular Analyte Field. ALL hereby grants to
GenMark, and GenMark hereby accepts, an exclusive (even as to ALL, but subject to the license back to ALL in Section 5.2) right and license, under the under the ALL IP Rights and ALL’s interest in Joint Collaboration IP Rights, to
make, have made, use, sell, offer for sale, and import in the Territory those Licensed Products utilizing Electrochemical Detection and capable of a throughput of *** for use in the Molecular Analyte Field. 

5.1.3 Non-Exclusive License for Enzyme Labels. ALL hereby grants to GenMark, and GenMark hereby accepts, a non-exclusive right and
license, under the under the ALL IP Rights and ALL’s interest in Joint Collaboration IP Rights, to make, have made, use, sell, offer for sale, and import in the Territory those Licensed Products utilizing Electrochemical Detection with an
Electrochemical Label that is an enzyme and capable of a throughput of *** for use in the Protein Analyte Field. 
 5.1.4
Sublicenses. The licenses granted to GenMark in this Section 5.1 shall include the right to grant sublicenses (each a “Sublicense”) to (i) Affiliates; and (ii) Third Parties to conduct research in the
Field, develop Licensed Products, market and sell Licensed Products, and manufacture Licensed Products (subject to Section 4.1) in collaboration with, or for the benefit of, GenMark (each a “Sublicensee”). In the event
of any Sublicense, GenMark shall continue to remain primarily liable for all liabilities and obligations under this Agreement, including the payment obligations set forth in Article 6. 

5.2 Option for License in Other Analyte Field. GenMark shall have the option to obtain an exclusive right and license, under the
ALL IP Rights and ALL’s interest in Joint Collaboration IP Rights, to make, have made, use, sell, offer for sale, and import in the Territory those Licensed Products utilizing GenMark e-Detection for use in the Other Analyte Field (the
“Option”). The Option shall be exercisable at any time within *** of the Effective Date (“Option Exercise Period”). In order to exercise the Option, GenMark shall, (i) within the Option Exercise Period, provide
ALL with written notice of its exercise of the Option and (ii) within five (5) Business Days of such notice, pay to ALL a one-time payment of *** . Upon exercise of the Option in accordance with this Section 5.2, the
Field shall be deemed to include the Other Analyte Field. Prior to expiry of the Option Exercise Period, ALL shall not grant or agree to grant any Third Party any rights or licenses, under the ALL IP Rights or ALL’s interest in Joint
Collaboration IP Rights, to make, have made, use, sell, offer for sale, and import in the Territory those Licensed Products utilizing GenMark e- Detection for use in the Other Analyte Field. 

 

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 17	  

					
	

	 		  	Execution Version

  

 5.3 Licenses to ALL 

5.3.1 License to ALL for Conduct of the Development Program. Subject to the terms of this Agreement, GenMark hereby grants to ALL a
non-exclusive, non-transferable, non- sublicenseable, right and license under the (i) ALL IP Rights and (to the extent exclusively licensed to GenMark hereunder), (ii) ALL’s interest in Joint Collaboration IP Rights (to the extent
exclusively licensed to GenMark hereunder), and (iii) GenMark IP Rights, in each case to make and use (but not sell or offer for sale) Licensed Products solely to the extent necessary for ALL to conduct those activities specified in the
Development Plan. 
 5.3.2 Non-Exclusive License to Collaboration Enabled Inventions. Subject to the terms of this
Agreement, GenMark hereby grants to ALL a non-exclusive, paid-up, world-wide, right and license under the Collaboration Enabled IP Rights to practice Collaboration Enabled Inventions solely with Digital Microfludics and to make, use, sell, offer for
sale and import products and apparatuses solely for use with Digital Microfluidics. The license granted in this Section 5.3.2 shall include the right to sublicense, provided that such sublicense is in conjunction with a license under
Digital Microfluidics intellectual property rights owned or Controlled by ALL. The license granted in this Section 5.3.2 shall be subject to the terms and conditions of any agreement pursuant to which GenMark obtains ownership or Control
of any Collaboration Enabled Inventions or Collaboration Enabled IP Rights. 
 5.4 Notice Rights; Right of First
Negotiation. 
 5.4.1 Notification of Intention to License Outside of Protein Analyte Field and
Molecular Analyte Field. During the period commencing on the Effective Date and ending the day after the third
(3rd) anniversary of the Effective Date, ALL may not
grant or promise to grant a Third Party any right or license under the ALL IP Rights or ALL’s interest in Joint Collaboration IP Rights, to make, use, sell, offer for sale or import any for product using Electrochemical Detection of targets
outside the Protein Analyte Field and the Molecular Analyte Field, excluding testing utilizing Sequencing, for use in human in-vitro Diagnostic Testing, without first having provided GenMark with at least forty-five (45) days prior notice of
ALL’s intention to do so. 
 5.4.2 Right of First Refusal. During the period commencing on the
Effective Date and ending the day after the first
(1st) anniversary of the Effective Date, ALL agrees
that, prior to granting or promising to grant a Third Party any right or license, under the ALL IP Rights or ALL’s interest in Joint Collaboration IP Rights, to make, use, sell, offer for sale or import any for product for use in the Molecular
Analyte Field utilizing Electrochemical Detection and limited to a simultaneous throughput of 1 or 2 samples (“Low-Throughput Product”), or if so requested by GenMark, the Parties will in good faith discuss and negotiate a license
to GenMark covering such Low-Throughput Products. If ALL and GenMark cannot agree on the terms and conditions of any such license within ninety (90) days of commencing such negotiations, then ALL may negotiate the terms and conditions of a
license covering the Low-Throughput Products with a Third Party; provided, however, that in each case, prior to licensing such Low-Throughput Products to a Third Party, ALL shall be obligated to offer to GenMark a license on
substantially the same terms and conditions as negotiated with the Third 

  

					
	Development Collaboration and License Agreement	  	 	Page 18	  

					
	

	 		  	Execution Version

  

 
Party. If GenMark does not accept such terms and conditions for such license within fifteen (15) days of the date of offer by ALL (the “Decision Period”), then ALL may enter
into the license covering such Low-Throughput Products with the Third Party; provided that if ALL does not enter into such license with such Third Party within ninety (90) days of GenMark’s decline of the terms and conditions
or the expiration of the Decision Period such Low-Throughput Products shall again be subject to the provisions of this Section 5.4.2. 
 5.5 Sale of Products to ***. During the Term of this Agreement, GenMark will not enter into any agreement or other commitment that would restrict GenMark from selling to *** , a Delaware
corporation, having its principal place of business at *** , products that are developed and/or commercialized using any ALL IP Rights, ALL products or services of ALL. Notwithstanding the foregoing, nothing in this Agreement shall prevent GenMark
from entering into an agreement or other commitment that restricts GenMark from selling to *** in a manner required by Applicable Law. 
 5.6 No Implied Licenses. Each Party acknowledges that the licenses granted under this Article 4 are limited to the scope expressly granted, and all other rights under a Party’s Patents
and other intellectual property rights are expressly reserved to the granting Party. Where a license granted by one Party to the other Party under this Article 4 is for a particular purpose or with respect to a particular product, the
granting Party retains all of its rights with respect to those intellectual property rights for those purposes not expressly licensed under this Agreement. 
 5.7 Limitations on ALL IP, CEA IP, *** IP and *** IP. Notwithstanding anything in this Article 5 (or otherwise in the Agreement) to the contrary, GenMark acknowledges and agrees that the
license rights granted to it in this Agreement are subject to limitations set forth in this Section 5.7. 
 5.7.1
Within thirty (30) days of GenMark granting a Sublicense under any *** IP, GenMark shall provide written notice, along with current contact information, to the *** and ALL. Any Sublicense of the *** IP by GenMark shall expressly prohibit
further sublicense of the *** IP by a Sublicenseee without ALL’s written consent (which consent shall not be unreasonably withheld or delayed by ALL, but remains subject to approval by the Reagents in accordance with Section 3.1 of the ***
Agreement). 
 5.7.2 The licenses granted to GenMark in this Article 5 under the CEA IP are: (i) non-exclusive in
the “Defense & Security Field” (as that phrase is defined in the CEA Agreement) to the extent required by Section 2.1(b) of the CEA Agreement; and (b) subject to the rights retained by CEA pursuant to Sections 2.2 of the
CEA Agreement. 
 5.7.3 The licenses granted to GenMark in this Article 5 under the *** IP are subject to rights in ***
IP retained by *** pursuant to Sections 2.2 of the *** Agreement. Except as authorized by Section 2.1(d) of the *** Agreement, GenMark shall require that any of its Sublicensees agree to undertake no further sublicenses of any of the *** IP
without ALL’s written consent (which consent shall not be unreasonably withheld or delayed by ALL, but remains subject to approval by *** in accordance with Section 2.1(d) of the *** Agreement). 

 

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 19	  

					
	

	 		  	Execution Version

  

 5.8 Rights Upon Termination of ALL’s Third Party Licenses. GenMark shall
have the rights of sublicensees specified Section 11.4(d) of the *** Agreement, and ALL shall promptly notify GenMark upon any termination of the *** Agreement. Any termination of the *** agreement shall be subject to Section 3.5 of the
*** Agreement, and ALL shall promptly notify GenMark upon any termination of the *** Agreement. ALL shall promptly notify GenMark upon any termination of the CEA Agreement. 
 5.9 Changes to ALL Agreements. Neither ALL nor any ALL Affiliate shall, without GenMark’s prior written consent, make any change to the CEA Agreement, *** Agreement, *** Agreement, or the
intercompany agreement between ALL and Advanced Liquid Logic France S.A.S. dated October 1, 2011, that materially adversely affects the overall rights granted to GenMark under this Agreement or places any material additional burden or
obligation on GenMark, its Affiliates or Sublicensees. GenMark agrees that a change to the *** Agreement changing the exclusive nature of the license granted in Section 2.1 of the *** Agreement to a non-exclusive license shall not be considered
to materially adversely affect the overall rights granted to GenMark under this Agreement. 
 ARTICLE 6: PAYMENTS

 6.1 Up-Front Payment. In consideration for the rights granted and promises made hereunder, GenMark shall, within
thirty (30) days of the Effective Date, pay to ALL a one-time, non-refundable, non-creditable payment of two hundred fifty thousand dollars (US$250,000). 
 6.2 Stock Purchase. On the Effective Date, ALL and GenMark will execute the “Stock Purchase Agreement” attached hereto as Schedule B, pursuant to which GenMark will
purchase, and ALL will sell, subject to the terms, conditions and contingencies set forth in the Stock Purchase Agreement, one million dollars (US$1,000,000) of ALL preferred stock. 

6.3 Development Program Costs. 
 6.3.1 Invoicing. Once each month, ALL shall submit to GenMark a single written invoice detailing the ALL Development Program Costs due to ALL pursuant to Section 2.4. Along with each
such written invoice, ALL shall provide GenMark a report for the invoiced period, which report details the ALL Development Program Costs incurred during such period, including a detailed break-down of the direct (including the identity of each
individual for which direct costs were incurred the their time spent on the Development Plan activities), indirect costs incurred, and a brief summary of the work performed. 
 6.3.2 Payment. Within thirty (30) days of receipt of an invoice issued pursuant to Section 6.3.1 and not disputed by GenMark, GenMark shall pay to ALL the invoiced amount.
Notwithstanding the foregoing, ALL shall not be entitled to payment for any costs incurred on account of activities not specified in the Development Plan, unless ALL has obtained prior written authorization from GenMark for such excess costs. Late
payment of undisputed amounts invoiced pursuant to Section 6.3.1 shall be subject to a late payment charge equal to 1.0% per month, or the maximum rate allowed by law, whichever is less. 

 

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 20	  

					
	

	 		  	Execution Version

  

 6.4 Development Milestones. In consideration of the rights and licenses granted
to GenMark under this Agreement, GenMark shall make the following payments within thirty (30) days after the first achievement with an Instrument Licensed Product or Consumable Licensed Product of the milestone events listed below: 

 

					
	 Milestone Event
	  	Milestone Payment
(in US Dollars)	 
	 ***
	  	 	*	** 
	 ***
	  	 	*	** 
	 ***
	  	 	*	** 
	 ***
	  	 	*	** 
	 ***
	  	 	*	** 

 For the purpose of determining achievement of the foregoing milestones the following definitions shall
apply: 
 *** 
 *** 
 *** 
 6.5 Other Analyte Field Milestone Payment. Provided that GenMark has exercise the Option, GenMark shall pay ALL a one-time payment
of            ***            within forty-five (45) days of the end of the Calendar Quarter during which the
aggregate amount of Net Sales of Consumable Licensed Products for use solely in the Other Analyte Field, together with a pro-rata share of Net Sales of those Consumable Licensed Products formulated for and sold for use in both the Other Analyte
Field and either the Protein Analyte Field or Molecular Analyte Field, first reaches        ***        . 

 

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 21	  

					
	

	 		  	Execution Version

  

 6.6 Single Milestone Payment. With respect to each set of milestone payments to
be made hereunder, only one set shall ever be due and payable, regardless of the number of Licensed Products developed, approved or cleared, or sold, or whether a Licensed Product is discontinued after a milestone payment has been made. All
milestone payments payable hereunder are non-refundable and non-creditable against any other payments hereunder. 
 6.7
Royalties on Instrument Licensed Products. In consideration of the rights and licenses granted to GenMark under this Agreement, in each Calendar Quarter during the Term of this Agreement in which GenMark records Net Capital Sales of an
Instrument Licensed Product, and subject to and in accordance with the terms and conditions of this Agreement, GenMark shall pay to ALL an amount equal
to            ***            of Net Capital Sales of Instrument Licensed Products Covered by Valid Claim within the ALL IP Rights
in the country of the Territory in which such Instrument Licensed Product is sold. 
 6.8 Transfer Price of ALL
Components. During the Term of this Agreement during which GenMark is supplied ALL Components pursuant to the Supply Agreement, GenMark shall pay ALL, for each ALL Component supplied under the Supply Agreement, a transfer price equal to the sum
of:            ***            . 
 6.9 Timing of Royalty Payments. All royalty payments due pursuant to Section 6.7 and, if applicable, Section 4.5, shall be paid in quarterly installments and be paid within forty-
five (45) days following the end of each Calendar Quarter. 
 6.10 Timing of Transfer Price Payments. The timing of
amounts due pursuant to Section 6.8 shall be set forth in the Supply Agreement 
 6.11 Deductions from
Payments. If in GenMark’s reasonable business judgment it is necessary or desirable to seek a license or immunity from suit from any Third Party in order for GenMark its Affiliates, distributors or Sublicensees, to exercise or use the
rights granted to GenMark herein, or GenMark its Affiliates, distributors or Sublicensees, is otherwise required to pay to any Third Party any fee, royalty or other payment in connection with a right or license under any Third Party Digital
Microfluidics or Digital Microfludies Related intellectual property to practice any Digital Microfluidics or Digital Microfludics Related technology for a Licensed Product under this Agreement, GenMark shall have the right to set off any amounts
paid to such Third Party, including fee, royalty or other payment, against payment of up to            ***            of the
royalty or Additional Margin payments otherwise payable hereunder; provided that in no event shall royalties or Additional Margin otherwise payable to ALL hereunder be reduced to less than
            ***            of what would otherwise be owed be prior to any set off taken under this Section 6.11.
Such right of offset shall be in addition to, and not in lieu of, any other rights or claims GenMark may have under this Agreement or otherwise. Prior to GenMark engaging in formal negotiations to incur any obligation to pay any Third Party any fee,
royalty or other payment in connection with a right or license under any Third Party Digital Microfluidics intellectual property to practice any Digital Microfluidics technology for a Licensed Product under this Agreement, GenMark shall notify ALL
of its intent to do so, and ALL shall have 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 22	  

					
	

	 		  	Execution Version

  

 thirty (30) days, or such other time as the Parties may agree, to obtain such right or license for
the benefit of GenMark prior to GenMark incurring such obligation. Nothing in this Section 6.11 shall limit the rights of GenMark set forth in Section 9.5. 
 6.12 Additional Royalty Terms. 
 6.12.1 Single Royalty.
Notwithstanding anything herein to the contrary, with respect to any Licensed Product, only a single royalty or Additional Margin payment shall be due and payable, regardless of whether such Licensed Product is covered by more than one Valid Claim.

 6.12.2 Royalty Term: Fully Paid Licenses. Where tied to a Valid Claim, royalties and Additional Margin under this
Article 6, and, if applicable, Section 4.5, are payable only during time periods in which sale of the applicable Licensed Product is Covered by a Valid Claim in the applicable country. Upon expiration of the obligation to pay such
royalties for a particular Licensed Product in a given country, the licenses granted to the Party under this Agreement with respect to such Licensed Product in such country shall become fully paid and irrevocable; provided that, in the event of a
gap in coverage by a Valid Claim, royalties and Additional Margin under this Article 6, and, if applicable, Section 4.5, shall become payable again following the expiration of any time periods in which sale of the applicable
Licensed Product is temporarily not Covered by a Valid Claim in the applicable country. 
 ARTICLE 7: REPORTS, AUDITS AND
FINANCIAL TERMS 
 7.1 Royalty Reports. Beginning following the First Commercial Sale of a Licensed Product, within
forty-five (45) days after the end of each Calendar Quarter in which a payment under Section 6.9 or 6.10, or, if applicable, Section 4.5, is required to be made, GenMark shall send ALL a report of Net Sales of the
Licensed Products upon which such payment is based, which report sets forth for such Calendar Quarter the following information: (i) total Net Sales of all Licensed Products sold in the Territory during such Calendar Quarter, (ii) Net
Sales on a country-by-country basis, (iii) Net Sales on an Instrument Licensed Product and Consumable Licensed Product basis; (iv)the exchange rate used to convert Net Sales from the currency in which they are earned to United States dollars;
and (v) the total royalty payments due. 
 7.2 Additional Financial Terms. 

7.2.1 Currency. All references to “dollars” or “$” means the legal currency of the United States. All payments
to be made under this Agreement shall be made in United States dollars, unless expressly specified to the contrary herein. Amounts invoiced in a currency other than dollars must be expressed in the United States dollar equivalent as well as any
local currency. Net Sales outside of the United States shall be first determined in the currency in which they are earned and shall then be converted into an amount in United States dollars. All currency conversions shall use the conversion rate
reported by Reuters Ltd. on the last Business Day of the Calendar Quarter for which such payment is being determined. 

  

					
	Development Collaboration and License Agreement	  	 	Page 23	  

					
	

	 		  	Execution Version

  

 7.2.2 Payment Type. Amounts paid by one Party to the other under this Agreement
shall be paid in U.S. dollars, in immediately available funds, by means of wire transfer to an account identified by the payee. 

7.2.3 Withholding of Taxes. Each Party may withhold from payments due to the other Party amounts for payment of any withholding
tax that is required by law to be paid to any taxing authority with respect to such payments. The Party withholding the tax shall provide to the other Party all relevant documents and correspondence, and shall also provide to the Party from whose
payment that tax was withheld any other cooperation or assistance on a reasonable basis as may be necessary to enable that Party subject to withholding to claim exemption from such withholding taxes and to receive a full refund of such withholding
tax or claim a foreign tax credit. The Party withholding the tax shall give proper evidence from time to time as to the payment of such tax. The Parties shall cooperate with each other in seeking deductions under any double taxation or other similar
treaty or agreement from time to time in force. Such cooperation may include GenMark making payments from a single source in the U.S., where possible. 
 7.2.4 Blocked Currency. If, at any time, legal restrictions prevent the prompt remittance of part or all royalties or other payments due with respect to any country where a Licensed Product is
sold, payment shall be made in cash through such lawful and reasonable means or methods as the GenMark may determine. When in any country, the law or regulations prohibit both the transmittal and deposit of royalties or other payments; GenMark shall
continue to report all such amounts, but may suspend payment for as long as such prohibition is in effect. As soon as such prohibition ceases to be in effect, all amounts that would have been obligated to be transmitted or deposited, but for the
prohibition, shall forthwith be deposited or transmitted promptly. 
 7.3 Accounts and Audit. 

7.3.1 Records. Each Party shall keep complete and accurate records containing sufficient detail on the particulars of Net Sales,
the calculation of royalties, and the particulars of and calculation of ALL Development Program Costs (as applicable) to enable such to be verified. Each Party shall keep such books of account and the supporting data and other records at its
principal place of business. Such books and records must be maintained available for examination in accordance with this Section for three (3) Calendar Years after the end of the Calendar Year to which they pertain, and otherwise as reasonably
required to comply with GAAP. 
 7.3.2 Appointment of Auditor. Each Party may appoint an internationally- recognized
independent accounting firm reasonably acceptable to the audited Party to inspect the relevant books of account of the audited Party to verify any reports or statements provided, or amounts paid or invoiced (as appropriate), by that audited Party.
The independent accounting firm (and any individuals, if applicable) appointed to perform the examination under this Agreement must execute a confidential disclosure agreement with the audited Party, or otherwise be subject to terms governing
non-use and non-disclosure of information that the audited Party has agreed in writing are acceptable. 

  

					
	Development Collaboration and License Agreement	  	 	Page 24	  

					
	

	 		  	Execution Version

  

 7.3.3 Procedures for Audit. Each Party may exercise its right to have the other
Party’s relevant records examined only during the three (3) year period during which the audited Party is required to maintain records, no more than once in any consecutive four (4) Calendar Quarter period, and only once with respect
to records covering any specific period of time. The audited Party is required to make its records available for inspection only during regular business hours, only at such place or places where such records are customarily kept, and only upon
receipt at least thirty (30) days written advance notice from the other Party. 
 7.3.4 Audit Report. The
independent accountant will be instructed to provide an audit report containing its conclusions regarding the audit, and specifying whether the amounts paid were correct, and, if incorrect, the amount of any underpayment or overpayment. The
independent accountant further will be instructed to provide that audit report first to the audited Party, and will be further instructed to redact any proprietary information of the audited Party not relevant to the calculation of royalties or ALL
Development Program Costs (as applicable) prior to providing that audit report to the other Party. That audit report shall be deemed to be Confidential Information of the audited Party, and used only for purposes germane to this Section. 

7.3.5 Underpayment and Overpayment. After review of the auditor’s report: (i) if there is an uncontested underpayment by
the audited Party for the period in question, then the audited Party shall pay to the other Party the full amount of that uncontested underpayment, and (ii) if there is an uncontested overpayment by the audited Party for the period in question,
then the other Party shall provide to the audited Party a credit against future payments (such credit equal to the full amount of that overpayment), or, if the audited Party is not obligated to make any future payments, then the other Party shall
pay to the audited Party the full amount of that overpayment. Contested amounts are subject to dispute resolution under Article 14. If the total amount of any underpayment (as agreed to by the audited Party or as determined under Article
14) exceeds ten percent (10%) of the amount previously paid by the audited Party for the period subject to audit (as long as that period is at least four (4) consecutive Calendar Quarters), then the audited Party shall pay the
reasonable costs for the audit. 
 7.4 Rights Regarding Consolidation of ALL Financial Data. If, at any time during the
term of this Agreement, compliance with any term or condition of this Agreement would, in GenMark’s opinion and with the concurrence of GenMark’s independent auditors, require GenMark to consolidate ALL within GenMark’s financial
statements in order to comply with FIN46R or any other applicable accounting standard of a nationally or internationally recognized standard setting body in effect at that time, then upon GenMark’s request, ALL shall cooperate with GenMark with
respect thereto, including preparing and providing to GenMark any information, such as ALL’s financial statements and forecast, reasonably required for GenMark to prepare a consolidated financial statement. GenMark shall reimburse ALL for its
reasonable expenses incurred in the preparation of any information requested by GenMark, and not already available, under this Section. 

  

					
	Development Collaboration and License Agreement	  	 	Page 25	  

					
	

	 		  	Execution Version

  

 ARTICLE 8: INTELLECTUAL PROPERTY; PATENT PROSECTION AND MAINTENANCE 

8.1 Disclosure of Inventions. Each Party shall promptly disclose to the other Party any inventions or other Technical Information
and Materials created, discovered, conceived or reduced to practice pursuant to the Development Program and the activities in the Development Plan. During the Development Term and the remainder of the Term of the Agreement, ALL shall, upon
GenMark’s request, disclose to GenMark all Patents within ALL IP Rights, (including in each case, any such Patents of which ALL acquires Control after the Effective Date). 

8.2 Ownership of IP Rights. 
 8.2.1 GenMark Owned IP Rights. As between the Parties, GenMark will solely own all right, title and interest in and to the GenMark IP Rights and, subject to the rights and licenses granted in
Section 5.3.2, the Collaboration Enabled IP Rights. 
 8.2.2 ALL Owned IP Rights. As between the Parties, ALL
will solely own all right, title and interest in and to the ALL IP Rights, subject to the rights and licenses granted in Article 5. 
 8.2.3 Joint Collaboration Inventions. The Parties shall jointly own all Joint Collaboration Inventions, subject to the rights and licenses granted in Article 5. Subject to the licenses
granted by one Party to the other under this Agreement, each Party retains full ownership rights (including as provided under 35 U.S.C. §262) in and to such Joint Collaboration Inventions, for any field, and including the right to license and
sublicense, and to freely exploit, transfer or encumber its ownership interest, without the consent of, or payment or accounting to, the other Party. Each Party hereby waives any right it may have under the Applicable Law of any jurisdiction to
require such payment, accounting, or consent with respect to Joint Collaboration Inventions. Each Party shall cooperate with the other Party to effectuate ownership of any Joint Collaboration Inventions, including as set forth in
Section 8.3.3. 
 8.3 Assignments. 
 8.3.1 ALL Collaboration Inventions. GenMark shall require all of its employees, contractors and agents, and any Affiliates and Third Parties working on its behalf under this Agreement (and their
respective employees, contractors and agents), to assign to ALL all right, title and interest in and to any ALL Collaboration Inventions created, discovered, conceived or reduced to practice by such employees, contractors or agents or Affiliates or
Third Parties. 
 8.3.2 GenMark Collaboration Inventions. ALL shall require all of its employees, contractors and agents,
and any Affiliates and Third Parties working on its behalf under this Agreement (and their respective employees, contractors and agents), to assign to GenMark all right, title and interest in and to any GenMark Collaboration Inventions created,
discovered, conceived or reduced to practice by such employees, contractors or agents or Affiliates or Third Parties. 

  

					
	Development Collaboration and License Agreement	  	 	Page 26	  

					
	

	 		  	Execution Version

  

 8.3.3 Cooperation. The Parties shall cooperate with each other to effectuate
ownership of any intellectual property rights as set forth in this Agreement, including, but not limited to, by executing and recording documents. 
 8.4 Patent Prosecution and Maintenance. 
 8.4.1 Definition. For
purposes of this Section 8.4, “Prosecution and Maintenance” or “Prosecute and Maintain.” with regard to a particular Patent, means the preparation, filing, prosecution and maintenance of such Patent, as
well as re-examinations, reissues, applications for patent term extensions and the like with respect to that Patent, together with the conduct of interferences, the defense of oppositions and other similar proceedings with respect to that Patent.

 8.4.2 GenMark Controlled Prosecution and Maintenance. As between the Parties, GenMark shall, at its sole discretion
and expense, have the sole right (but not the obligation) to Prosecute and Maintain Patents within the GenMark IP Rights and Collaboration Enabled IP Rights. 
 8.4.3 ALL Controlled Prosecution and Maintenance. As between the Parties, ALL shall, at its sole discretion and expense, have the sole right (but not the obligation) to Prosecute and Maintain
Patents within the ALL IP Rights, subject to Section 8.4.5. ALL shall, within a reasonable amount of time following issue, advise GenMark of the issuance during the Term of any Patent that falls within the ALL IP Rights. 

8.4.4 Prosecution and Maintenance of Joint Collaboration Patents. Subject to the provisions of this Section and
Section 8.4.5, the Parties shall jointly decide on a strategy for the Prosecution and Maintenance of Patents claiming Joint Collaboration Inventions (“Joint Collaboration Patents”), including deciding on (i) the
content of the application and (ii) the countries in which Prosecution and Maintenance should be conducted. ALL and GenMark shall, unless otherwise agreed to, select a mutually agreeable outside counsel (“Outside Patent
Counsel”) to be responsible for the Prosecution and Maintenance of Joint Collaboration Patents. 
 (a)
Cooperation. The Parties shall cooperate and assist each in the Prosecution and Maintenance of respect Joint Collaboration Patents, including (i) consulting with the other Party after receiving any substantial action or development in
the Prosecution and Maintenance of such Patent and (ii) making its relevant scientists and scientific records reasonably available. In addition, each Party shall sign and deliver, or use reasonable efforts to have signed and delivered, at no
charge to the other Party, all documents necessary in connection with such Prosecution and Maintenance. 
 (b) Instructions
to Outside Patent Counsel. With respect to any Joint Collaboration Patents, the Outside Patent Counsel (if any) shall be instructed to (i) keep the Parties informed regarding the Prosecution and Maintenance thereof; (ii) promptly
furnish to 

  

					
	Development Collaboration and License Agreement	  	 	Page 27	  

					
	

	 		  	Execution Version

  

 each Party a copy of such Patent and copies of documents relevant to such Prosecution and Maintenance,
including copies of correspondence with any patent office, foreign associates and outside counsel; and (iii) act on the Parties’ instructions relating to such Prosecution and Maintenance. 

(c) Costs. Unless otherwise mutually agreed by the Parties, both during and after the Term of this Agreement, all costs of
prosecuting and maintaining Joint Collaboration Patents shall be shared equally by the Parties. 
 8.4.5 Abandonment of
Prosecution and Maintenance. With respect to any Joint Collaboration Patent, a Party (the “Abandoning Party”) may elect not to Prosecute and Maintain such Patents (whether worldwide or with respect to any particular country) and
share the costs therefore (in accordance with Section 8.4.4(c)). including electing not to file a patent application with respect thereto or to allow any such Patent to lapse or become abandoned or unenforceable. Prior to any such
election becoming effective, the Abandoning Party shall promptly notify the other Party (the “Remaining Party”) in writing (which such notice shall be at least sixty (60) days prior to the lapse or abandonment of any such
Patent). Thereafter, the Remaining Party may, but is not required to, undertake, at its sole expense and in its sole discretion, the Prosecution and Maintenance of such Patent. In the event that the Remaining Party undertakes such Prosecution and
Maintenance, (i) the Abandoning Party shall assign all right, title and interest in and to such Patent to the Remaining Party, (ii) the Abandoning Party shall cooperate as set forth in Section 8.4.4(a), and
(iii) notwithstanding anything in this Agreement to the contrary, if ALL is the abandoning Party, such Patent shall no longer serve as the basis of any royalty obligation to ALL under Article 6 or, if applicable, Section 4.5,
or Additional Margin. 
 8.5 Patent Interferences. If an interference is declared by the U.S. Patent and Trademark Office
(a) between (i) a claim in one or more Patents within the ALL IP Rights or a Joint Collaboration Patent and (ii) a claim in one or more Patents within the GenMark IP Rights, where at least one of such claims would, but for the
licenses in this Agreement, be infringed by the making, using, offering for sale, selling or importing of a Licensed Product; then the Parties shall in good faith establish within thirty (30) days of the declaration of such interference, or
such other time as agreed upon, a mutually agreeable process to resolve such interference in a reasonable manner (including, without limitation, control and cost sharing), in conformance with all applicable legal standards. 

8.6 Inventorship. Any determination of inventorship with respect to any Collaboration Invention shall be made in accordance with
the applicable United States patent laws. 
 8.7 CREATE Act. It is the intention of the Parties that this Agreement is a
“joint research agreement” as that phrase is defined in 35 USC §103(c)(3). In the event that either Party to this agreement intends to overcome a rejection of a claimed Collaboration Invention pursuant to the provisions of 35 USC
§103(c)(2), such party shall first obtain the prior written consent of the other Party. Following receipt of such written consent, such Party shall limit any amendment to the specification or statement to the patent office with respect to this
Agreement to that which is strictly required by 35 USC §103(c) and the rules and regulations promulgated 

  

					
	Development Collaboration and License Agreement	  	 	Page 28	  

					
	

	 		  	Execution Version

  

 thereunder and which is consistent with the terms and conditions of this Agreement (including the scope
of the Development Program). To the extent that the Parties agree that, in order to overcome a rejection of a claimed Collaboration Invention pursuant to the provisions of 35 USC §103(c)(2), the filing of a terminal disclaimer is required or
advisable, the Parties shall first agree on terms and conditions under which the patent application subject to such terminal disclaimer and the patent or application over which such application is disclaimed shall be jointly enforced, to the extent
that the Parties have not previously agreed to such terms and conditions. In the event that GenMark enters into an agreement with a Third Party, permitted under this Agreement, with respect to the further development or commercialization of a
Licensed Product, ALL shall, upon GenMark’s request, similarly enter into such agreement with the Third Party for the purposes of furthering the Parties’ objectives under this Agreement, provided that such agreement does not place any
material obligation on ALL. 
 ARTICLE 9: ENFORCEMENT OF IP RIGHTS; DEFENSE OF THIRD PARTY INFRINGEMENT CLAIMS 

9.1 Notice. Each Party shall promptly notify the other Party upon learning of any (i) actual or suspected infringement or
misappropriation (collectively, an “Infringement”) of the ALL IP Rights or Joint Collaboration IP Rights by a Third Party within the scope of the rights and licenses granted to GenMark in Section 5.1, or (ii) claim
by a Third Party of invalidity, unenforceability or non-infringement of a Patent within the ALL IP Rights or a Joint Collaboration Patent. 
 9.2 Infringement Action. 
 9.2.1 GenMark IP Rights. As between the
Parties, GenMark shall have the sole right, but not the obligation, to seek to abate any Infringement of the GenMark IP Rights and/or Collaboration Enabled IP Rights by a Third Party, or to file suit against any such Third Party. ALL shall
reasonably cooperate with GenMark (as may be reasonably requested by GenMark), including, if necessary, by being joined as a party. 
 9.2.2 ALL IP Rights and Exclusively Licensed Joint Collaboration IP Rights. 

(a) GenMark shall have the sole right, but not the obligation, to seek to abate any Infringement of the ALL IP Rights and/or Joint
Collaboration Patents by a Third Party within the scope of the exclusive licenses granted to GenMark in Sections 5.1.1 and 5.1.2, or to file suit against any such Third Party (including as a counter-claim or similar action in a suit initiated
by a Third Party) for Infringement of the ALL IP Rights and/or Joint Collaboration Patents by a Third Party within the scope of the exclusive licenses granted to GenMark; provided that: 

(i) if GenMark seeks to abate any Infringement of, or files suit to enforce the, *** IP, then (A) any legal counsel chosen by
GenMark therefor shall be reasonably acceptable to ***, and (B) to the extent that GenMark (1) is unsuccessful in persuading the Third Party to desist, and (2) fails to have filed suit against such Third Party, in each case within a
reasonable time after GenMark first becomes aware of the basis for such 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 29	  

					
	

	 		  	Execution Version

  

 action, and the undertaking of such action is, at such time, commercially reasonable under the
circumstances, then *** will have the right, at its sole discretion, to prosecute such infringement under its sole control and sole expense in accordance with Section 7.2(b) of the *** Agreement. 

(ii) if GenMark seeks to abate any Infringement of, or wishes to file suit to enforce the *** IP, GenMark shall, prior to notifying any
Third Party of an alleged infringement of any *** IP or taking any action described in Section 9.2.2(a) to enforce any *** IP, provide ALL notice of GenMark’s desire to do so. If so requested by GenMark, ALL shall use its good faith
efforts to obtain *** consent for GenMark to exercise its rights under Section 9.2.2(a) subject to *** rights pursuant to Section 8.2 and 8.3 of the *** Agreement. 

(b) To the extent outside the scope of the exclusive licenses granted to GenMark in Sections 5.1.1 and 5.1.2, but within the
scope of the non-exclusive licenses granted to GenMark in Section 5.1.3, ALL shall have the first right, but not the obligation, to seek to abate Infringement of the ALL IP Rights by a Third Party, or to file suit against any such Third
Party. If ALL does not, within one hundred twenty (120) days of receipt of a notice under Section 9.1 or receipt of a notice from GenMark regarding such Infringement, take steps to abate such Infringement, or file suit to enforce
the ALL IP Rights against such Third Party, GenMark shall have the right (but not the obligation) to take action to enforce the ALL IP Rights (to the extent licensed to GenMark under this Agreement) against such Third Party. The non-controlling
Party shall cooperate with the Party controlling any such action pursuant to this Section 9.2.2 (as may be reasonably requested by the controlling Party), including, if necessary, by being joined as a party, and the Party controlling any
such action shall keep the other Party updated with respect to any such action, including providing copies of all documents received or filed in connection with any such action. To the extent outside the scope of the exclusive licenses granted to
GenMark in Sections 5.1.1 and 5.1.2 and the non-exclusive licenses granted to GenMark in Section 5.1.3, ALL shall have the sole right, but not the obligation, to seek to abate Infringement of the ALL IP Rights by a Third Party, or
to file suit against any such Third Party; provide that ALL consult with, and keep GenMark informed with respect to any such actions that may affect the scope, validity or enforceability of the ALL Patent Rights licensed to GenMark. The foregoing
rights of the Parties shall be subject to the following: 
 (i) GenMark shall have no rights under this
Section 9.2.2(b) to seek abatement of such Infringement of *** IP, or to file suit with respect to enforce the *** IP, unless otherwise agreed by *** . 
 (ii) to the extent that such ALL IP Rights involve *** IP, and ALL or GenMark (A) is unsuccessful in persuading the alleged infringer to desist, and (B) fails to have initiated an infringement
action, in each case within a reasonable time after ALL or GenMark first becomes aware of the basis for such action, and the undertaking of such action is, at such time, commercially reasonable under the circumstances, then *** will have the right,
at its sole discretion, to prosecute such infringement under its sole control and sole expense in accordance with Section 7.2(b) of the *** Agreement. 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 30	  

					
	

	 		  	Execution Version

  

 (iii) if GenMark seeks to abate any Infringement of, or files suit to enforce, CEA IP
to which GenMark’s license is non-exclusive in accordance with Section 5.7.2, the right to do so shall be subject to Section 7.2(b) of the CEA Agreement. 
 9.2.3 Non-Exclusively Licensed Joint Collaboration IP Rights. In the event that an Infringement is of a Joint Collaboration IP Right not within the scope of the exclusive licenses granted to
GenMark in Sections 5.1.1 and 5.1.2, the Parties shall promptly discuss how to enforce such Joint Collaboration IP Right in the best interests of both Parties, considering appropriate actions of each Party, and the relevant times to take any
legal or other action. 
 9.3 Settlement. The Party controlling any such action described in Section 9.2.2
may not settle or consent to an adverse judgment, including any judgment which affects the scope, validity or enforcement of any ALL IP Rights or Joint Collaboration IP Rights, without the express written consent of the non-controlling Party (such
consent not to be unreasonably withheld), except that GenMark may settle or consent to an adverse judgment in any action described in Section 9.2.2(a) without obtaining consent from ALL unless any such settlement or consent judgment
would either impose a financial obligation upon ALL, or limit the scope of or invalidate any ALL IP Rights or Program IP Rights, in which event GenMark shall obtain ALL’s prior written consent (such consent not to be unreasonably withheld or
delayed). 
 9.4 Damages. 
 9.4.1 GenMark IP Rights. All monies recovered upon the final judgment or settlement of any action described in Section 9.2.1 shall be GenMark’s. 

9.4.2 Exclusive Rights. Unless otherwise mutually agreed by the Parties, all monies recovered upon the final judgment or
settlement of any action described in Section 9.2.2(a), shall be used: (i) first, to reimburse each of GenMark and ALL, on a pro rata basis for its out-of-pocket expenses relating to the action; (ii) second, any
remaining balance that represents compensation for GenMark’s or its Affiliates’ or Sublicensee’s lost sales, a reasonable royalty due to or lost profits of GenMark or its Affiliates or Sublicensees, shall be retained by or paid to
GenMark; provided, however, that any such amounts shall (after relevant adjustment to convert to Net Sales of Licensed Products) be subject to the royalty obligations set forth in Section 6.7, the Additional Margin in the transfer price
calculations of Section 6.8, and, if applicable, the royalty obligations set forth in Section 4.5; and (iii) third, any remaining amount that represents additional damages (for example, enhanced or punitive damages) shall be
allocated between the parties in amounts proportional to the split of amounts calculated in accordance with (ii) above. Notwithstanding the foregoing: 
 (a) All monies recovered upon the final judgment or settlement of any action described in Section 9.2.2(a) to the extent based upon the *** IP shall (x) first be allocated between GenMark
and *** in accordance with the distribution provisions set forth in Section 8.4 of the *** Agreement (as if GenMark were the “Licensee” under the *** Agreement and (y) any amounts allocated and paid to GenMark in accordance
(x) of this paragraph shall then be distributed in accordance with Section 9.4.2(i)-(iii) between ALL and GenMark, provided that any distribution to ALL in accordance with Section 9.4.2(i)-(iii) shall be
reduced by the amounts allocated to *** in accordance with this paragraph. 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 31	  

					
	

	 		  	Execution Version

  

 (b) All monies recovered upon the final judgment or settlement of any action described
in Section 9.2.2(a) to the extent it involves *** IP shall (x) first be allocated between GenMark and *** in accordance with the distribution provisions set forth in applicable part of Section 7.4 of the *** Agreement (as if
GenMark were “***” under the *** Agreement), and (y) any amounts allocated and paid to GenMark in accordance (x) of this paragraph shall then be distributed in accordance with Section 9.4.2(i)-(iii) between ALL
and GenMark, provided that any distribution to ALL in accordance with Section 9.4.2(i)-(iii) shall be reduced by the amounts allocated to *** in accordance with this paragraph. 

9.4.3 Non-Exclusive Rights. 
 (a) Unless otherwise mutually agreed by the Parties, all monies recovered upon the final judgment or settlement of any action described in Section 9.2.2(b), shall be used: 

(i) first, to reimburse each of ALL and GenMark, on a pro rata basis for its out-of-pocket expenses relating to the action; and

 (ii) second, (A) if ALL is the Party taking action to enforce the ALL IP Rights, any remaining balance shall be
retained by or paid to ALL (subject to any further obligations it may have under the CEA Agreement, the *** Agreement and the *** Agreement), or (B) if GenMark is the Party taking action to enforce the ALL IP Rights, (x) any remaining
balance that represents compensation for GenMark’s or its Affiliates’ or Sublicensee’s lost sales(if any) as a licensee of the ALL IP (if any), a reasonable royalty due to or lost profits (if any) of GenMark or its Affiliates or
Sublicensees as a licensee of the ALL IP, shall be retained by or paid to GenMark; provided, however, that any such amounts shall (after relevant adjustment to convert to Net Sales of Licensed Products) be subject to the royalty obligations set
forth in Section 6.7and 6.8, and, if applicable, Section 4.5, and calculation as Additional Margin; (y) any other amounts recovered by GenMark that otherwise constitute damages attributable to the lost sales or lost
profits of ALL or any other damages and losses incurred by ALL, or otherwise recoverable by ALL at law or equity, shall be paid to ALL (subject to any further obligations it may have under the CEA Agreement, the *** Agreement and the *** Agreement);
and (z) any remaining amounts that were not allocated in accordance with the preceding provisions and which represent additional damages (for example, enhanced or punitive damages) shall be retained by or paid to GenMark. 

(b) Notwithstanding the provisions of Section 9.4.3(a): 
 (i) All monies recovered upon the final judgment or settlement of any action described in Section 9.2.2(b) to the extent it based upon the *** IP shall (A) first be allocated between
GenMark and *** in accordance with the distribution provisions set forth in Section 8.4 of the *** Agreement (as if GenMark were the “Licensee” under the *** Agreement and (B) any amounts allocated and paid to GenMark in
accordance (A) above shall then be distributed in accordance with Section 9.4.3(a)(i) between ALL and GenMark, provided that any distribution to ALL in accordance with Section 9.4.3(a)(i) shall be reduced by the amounts
allocated to *** in accordance with this paragraph. 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 32	  

					
	

	 		  	Execution Version

  

 (ii) All monies recovered upon the final judgment or settlement of any action described
in Section 9.2.2(b) to the extent it involves *** IP, shall (x) first be allocated between the Party taking action under Section 9.2.2(b) and *** in accordance with the distribution provisions set forth in applicable
part of Section 7.4 of the *** Agreement (as if the Party taking action were “***” under the *** Agreement), and (y) any amounts allocated and paid to the Party taking action under Section 9.2.2(b) in accordance
(x) of this paragraph shall then be distributed in accordance with Section 9.4.3(a)(i) between ALL and GenMark, provided that if GenMark is the Party taking any action described in Section 9.2.2(b) any distribution to
ALL in accordance with Section 9.4.3(a)(i) shall be reduced by the amounts allocated to *** in accordance with this paragraph. 
 9.5 Third Party Suits Against GenMark. In the event that a Third Party shall make any claim or bring any suit or other proceeding against GenMark, or any of its Affiliates, distributors, sublicensees, or
customers, for infringement or misappropriation of any intellectual property rights with respect to the development, making, using selling, offering for sale, import or export of Licensed Product, GenMark shall have the right to defend and control
the defense of such claim, suit or other proceeding as well as to initiate and control any counterclaim or other similar action. At GenMark’s request, ALL shall cooperate with GenMark in defense of such claim, suit or other proceeding,
including by being joined as a party. Nothing in this Section 9.5 shall be deemed to diminish in any respect ALL’s right to defend and control the defense of any claim, suit or other proceeding against ALL; provided that the initiation and
control of any counterclaim or other similar action in such claim, suit or other proceeding shall be subject to Section 9.2.2. 
 ARTICLE 10: TERM AND TERMINATION 
 10.1 Term. The term of this
Agreement (the “Term”) shall commence on the Effective Date and, unless sooner terminated by mutual agreement or pursuant to any other provision of this Agreement, shall terminate on the date on which all obligations under this
Agreement between the Parties with respect to the payment of milestones or royalties with respect to Licensed Products have passed or expired. 
 10.2 Termination. 
 10.2.1 Material Breach. ALL may terminate this
Agreement for: (i) an Uncured Material Breach by GenMark of either GenMark’s obligation, subject to the terms and conditions of this Agreement, to make payments payable to ALL under this Agreement or GenMark’s obligations under
Section 2.1; or (ii) in accordance with Section 3.2.2. GenMark may terminate this Agreement for an Uncured Material Breach by ALL of Section 2.1; provided that the terminating Party give the breaching Party
written notice of such breach and the breach remains uncured after the expiration of sixty (60) days after such written notice was given; provided further that, if such breach is not capable of being cured within such sixty (60) day
period, the cure period shall be extended for such amount of time that the Parties agree to in writing is 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 33	  

					
	

	 		  	Execution Version

  

 reasonably necessary to cure such breach, so long as the breaching Party is using diligent efforts to do
so. An “Uncured Material Breach” is a material breach that has not been cured by the end of the cure period described in the preceding sentence. A termination for an Uncured Material Breach shall be effective upon the expiration of
the cure period. Any dispute as to whether a notice of termination pursuant to this Section 10.2.1 is proper, or whether a breach has occurred, is material or has been cured, shall be resolved under Article 14. In such event, if
the allegedly breaching Party is found to be in material breach, such breaching Party shall have sixty (60) days (or longer, as determined during the resolution of such dispute) to cure such material breach following resolution of such dispute.

 10.2.2 Bankruptcy. GenMark shall have the right to terminate this Agreement, upon written notice to ALL, in the event
that ALL seeks protection of any bankruptcy or insolvency law other than a reorganization; or a proceeding in bankruptcy or insolvency is filed by or against ALL, other than a reorganization, and such proceeding remains undismissed or unstayed for a
period of more than ninety (90) days, or there is an adjudication by a court of competent jurisdiction that ALL is bankrupt or insolvent. 
 10.2.3 Termination for Convenience. GenMark may terminate this Agreement at any time, with or without cause, upon sixty (60) days advanced written notice to ALL. 

10.3 Effect of Termination or Expiration. 
 10.3.1 Upon termination of this Agreement by ALL or GenMark pursuant to Section 10.2.1, or by GenMark pursuant to Section 10.2.2 or 10.2.3, (i) all rights and licenses granted
to either GenMark or ALL under Article 5, except the rights and licenses granted pursuant to Section 5.3.2. shall immediately terminate and (ii) upon the request of the disclosing Party, the receiving Party shall promptly
return to the disclosing Party or destroy all copies of Confidential Information received from such Party, and shall return or destroy, and document the destruction of, all summaries, abstracts, extracts, or other documents which contain any
Confidential Information of the other Party in any form, except that each Party shall be permitted to retain a copy (or copies, as necessary) of such Confidential Information for archival purposes or as required by any law or regulation. 

10.3.2 Termination or expiration of this Agreement, through any means and for any reason, shall not relieve the Parties of any obligation
accruing prior thereto, including the payment of all sums due and payable, and shall be without prejudice to the rights and remedies of either Party with respect to any antecedent breach of any of the provisions of this Agreement. 

10.4 Additional GenMark Rights on Certain Uncured Material Breaches. In addition to any other rights of GenMark under this
Agreement (including Section 4.4), upon either an Uncured Material Breach by ALL of Section 2.1 or a Change of Control of ALL, then upon written notice and request to ALL by GenMark, such notice provided to ALL either, as
applicable, (a) within sixty (60) days of any occurrence of an Uncured Material Breach by ALL of Section 2.1, or (b) any time following a Change of Control of ALL: (i) all licenses granted to ALL under
Section 5.3, except the rights and licenses granted pursuant to Section 5.3.2, shall immediately terminate; (ii) ALL shall disclose (and transfer as applicable) to GenMark all 

  

					
	Development Collaboration and License Agreement	  	 	Page 34	  

					
	

	 		  	Execution Version

  

 Technical Information and Materials owned or Controlled by ALL that are reasonably necessary or useful
to enable GenMark to continue to develop, manufacture, seek marketing approvals for Licensed Products within the scope of the licenses granted to GenMark in Section 5.1; and (iii) the Parties shall use diligent efforts to effect an
orderly transfer wind down Development Program, after which the Development Program and Development Term shall be deemed ended and expired and the provisions of Article 2 shall no longer apply. In the event that GenMark exercises its right to
obtain transfer of Technical Information and Materials owned or Controlled by ALL pursuant to this Section 10.4 (a) due solely to a Change of Control of ALL, GenMark shall reimburse ALL
for            ***            incurred by ALL for activities undertaken by ALL at GenMark’s request to effect such transfer;
or (b) for an Uncured Material Breach by ALL of Section 2.1, GenMark shall reimburse ALL
for            ***            incurred by ALL for activities undertaken by ALL at GenMark’s request to effect such transfer.

 10.5 Survival. In addition to as elsewhere explicitly set forth in this Agreement, Article 1, Article 8,
Article 13, Sections 4.4 (as applicable), 5.3.2, 10.3, 15.1, 15.4, 15.6, 15.12 and 15.16, and if and as applicable to Section 10.4, Sections 6.9. 6.11. 6.12 and Article 7 shall survive expiration or termination of this
Agreement for any reason. 
 ARTICLE 11: REPRESENTATIONS AND WARRANTIES 

11.1 ALL Representations. ALL hereby represents, warrants and covenants to GenMark that: 

11.1.1 ALL has the full right, power and authority, and has obtained all approvals, permits or consents necessary, to enter into this
Agreement and to perform all of its obligations hereunder and to grant the licenses provided hereunder. 
 11.1.2 ALL has not,
prior to the Effective Date, entered into and shall not, following the Effective Date, enter into any agreement and has not granted any now existing, or agreed to grant any future, license, right or privilege which agreement, license, right or
privilege conflicts in any way with this Agreement, the licenses granted hereunder, or ALL’s obligations hereunder. 

11.1.3 Subject to the encumbrances set forth in the CEA Agreement, *** Agreement and *** Agreement, and the government rights described
in Section 15.1, ALL is the sole and exclusive owner of, or Controls, the ALL IP Rights existing as of the Effective Date free and clear of any liens or encumbrances. 

11.1.4 To All’s knowledge, the ALL Patent Rights existing as of the Effective Date are valid and enforceable. 

11.1.5 As of the Effective Date, no claims of infringement, misappropriation or other conflict with any intellectual property rights or
other rights owned or controlled by any Third Party have been made or threatened with respect to the ALL IP Rights existing as of the Effective Date. 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 35	  

					
	

	 		  	Execution Version

  

 11.1.6 None of the ALL IP Rights existing as of the Effective Date is subject to any
outstanding injunction, judgment, order, ruling, or charge, and, to ALL’s knowledge no claim or actions is pending or threatened which challenges the legality, validity, enforceability, use, or ownership of any such ALL IP Rights, and ALL is
not aware of any facts or circumstances that indicate a likelihood of the foregoing. As of the Effective Date, no loss or expiration of any of the granted or issued patents of the ALL IP Rights is threatened, pending, or reasonably foreseeable,
except for patents expiring at the end of their statutory terms (and not as a result of any act or omission by the ALL, including a failure to pay any required maintenance fees). 

11.1.7 As of the Effective Date, ALL is not aware of any material infringement or misappropriation of the ALL IP Rights existing as of
the Effective Date by any Third Party. 
 11.1.8 ALL follows reasonable commercial practices common in the industry to protect
its proprietary and confidential information, including requiring its employees, consultants and agents to be bound in writing by obligations of confidentiality and non-disclosure, and requiring its employees, consultants and agents to assign to it
any and all inventions and discoveries discovered by such employees, consultants and/or agents made within the scope of, and during their employment, and only disclosing proprietary and confidential information to Third Parties pursuant to written
confidentiality and non-disclosure agreements 
 11.1.9 This Agreement is a legal and valid obligation binding upon ALL and
enforceable in accordance with its terms. 
 11.2 GenMark Representations. GenMark hereby represents and warrants the
following to ALL: 
 11.2.1 GenMark has the full right, power and authority, and has obtained all approvals, permits or consents
necessary, to enter into this Agreement and to perform all of its obligations hereunder. 
 11.2.2 This Agreement is a legal and
valid obligation binding upon GenMark and enforceable in accordance with its terms. 
 11.2.3 GenMark has not, prior to the
Effective Date, entered into and shall not, following the Effective Date, enter into any agreement that conflicts in any way with this Agreement or GenMark’s obligations hereunder. 

11.3 DISCLAIMER. THE WARRANTIES AND REPRESENTATIONS SET FORTH IN SECTIONS 11.1 AND 11.2 ARE IN LIEU OF ALL OTHER WARRANTIES
AND REPRESENTATIONS, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, VALIDITY, NON-INFRINGEMENT, AND ALL SUCH OTHER WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED.

  

					
	Development Collaboration and License Agreement	  	 	Page 36	  

					
	

	 		  	Execution Version

  

 ARTICLE 12: INDEMNIFICATION 

12.1 Indemnification by ALL. ALL shall defend, indemnify and hold harmless GenMark and its Affiliates and Sublicensees and their
respective officers, directors, employees and agents (“GenMark Indemnified Parties”) from and against any and all claims, suits or other actions made by a Third Party and all related losses, expenses, damages, costs and liabilities
(including reasonable attorneys’ fees) (collectively, “Losses”), arising out of (i) the material breach of any representation, warranty, covenant or obligation made by ALL under this Agreement, (ii) the negligence or
willful misconduct of ALL, its Affiliates or contractors, or their respective its officers, directors or employees in connection with the performance of their obligations under this Agreement, or (iii) ALL’s provision of the ALL Components
pursuant to this Agreement; provided, however, that the foregoing obligation shall not apply to the extent such Losses are attributable to (a) the material breach of any representation, warranty, covenant or obligation made by GenMark under
this Agreement, or (b) the negligence or willful misconduct of a GenMark Indemnified Party. 
 12.2 Indemnification by
GenMark. GenMark shall defend, indemnify and hold harmless ALL and its Affiliates and their respective its officers, directors, employees and agents (“ALL Indemnified Parties”) from and against any and all Losses, arising out of
(i) the material breach of any representation, warranty, covenant or obligation made by GenMark under this Agreement, (ii) the gross negligence or willful misconduct of GenMark, its Affiliates or contractors, or their respective officers,
directors or employees in connection with the performance of their obligations under this Agreement, or (iii) the production, marketing, distribution and sale of Licensed Products by GenMark; provided, however, that the foregoing obligation
shall not apply to the extent that such Losses are attributable to (a) the material breach of any representation, warranty, covenant or obligation made by ALL under this Agreement, (b) the negligence or willful misconduct of an ALL
Indemnified Party, or (c) the failure of an ALL Component to meet, or non-conformance of an ALL Component with, the specifications of such ALL Component as set forth in this Agreement or in any subsequent written purchase order or delivery
order entered into pursuant to this Agreement. 
 12.3 Procedure. The indemnities set forth in this Article 12 are
subject to the condition that the Party seeking the indemnity shall forthwith notify the indemnifying Party on being notified or otherwise made aware of any Losses and that the indemnifying Party defend and control any proceedings with the
indemnified Party being permitted to participate at its own expense (unless there shall be a conflict of interest which would prevent representation by joint counsel, in which event the indemnifying Party shall pay for the indemnified Party’s
counsel). The indemnifying party shall reasonably cooperate, at the cost of the indemnifying Party, in the investigation, defense and/or settlement of any such proceedings or indemnifiable matters. 

12.4 Settlement. The indemnifying Party may not settle any liability, claim, suit, action or expense, or otherwise consent to any
judgment, without the written consent of the indemnified Party (such consent not to be unreasonably withheld). 

  

					
	Development Collaboration and License Agreement	  	 	Page 37	  

					
	

	 		  	Execution Version

  

 12.5 GenMark Indemnification of *** and the ***. GenMark acknowledges and agrees
that it shall be bound by the additional indemnification obligations set forth on Exhibit 1 hereto, with respect to the indemnification of *** and the *** . 
 12.6 Insurance. 
 12.6.1 [Reserved] 

12.6.2 GenMark shall maintain insurance coverage consistent with Section 18.2, 18.3 and 18.4 of the *** Agreement. 

12.7 LIMITATION ON DAMAGES. NOTWITHSTANDING ANYTHING CONTAINED IN THIS AGREEMENT TO THE CONTRARY, IN NO EVENT SHALL EITHER PARTY
BE LIABLE FOR ANY SPECIAL, CONSEQUENTIAL OR INCIDENTAL DAMAGES (INCLUDING LOSS OF PROFITS) WHETHER BASED UPON BREACH OF WARRANTY, BREACH OF CONTRACT, NEGLIGENCE, STRICT TORT OR ANY OTHER LEGAL THEORY; PROVIDED, HOWEVER, THE FOREGOING SHALL NOT LIMIT
A PARTY’S OBLIGATION TO INDEMNIFY THE OTHER PARTY AGAINST LOSSES PURSUANT TO THIS ARTICLE 12. GENMARK FURTHER ACKNOWLEGES AND CONSENTS TO (A) THE WARRANTY DISCLAIMERS AND LIMITATION OF LIABILILITY PROVISIONS SET FORTH IN ARTICLE 17
OF THE *** AGREEMENT AND (B) THE WARRANTY DISCLAIMERS AND LIMITATION OF LIABILITY PROVISIONS SET FORTH IN SECTIONS 8.1-8.3 OF THE *** AGREEMENT. 
 ARTICLE 13: CONFIDENTIALITY 
 13.1 Confidential Information. During
the Term of this Agreement and for five (5) years thereafter without regard to the means of termination: (i) ALL shall not use, for any purpose other than the purpose of this Agreement, or reveal or disclose to any Third Party GenMark
Confidential Information; and (ii) GenMark shall not use, for any purpose other than the purpose of this Agreement, or reveal or disclose to any Third Party ALL Confidential Information. The Parties shall take reasonable measures to assure that
no unauthorized use or disclosure is made by others to whom access to such information is granted. 
 13.2 Exceptions.
Notwithstanding the foregoing, a Party may use and disclose Confidential Information (including any GenMark Confidential Information and ALL Confidential Information) as follows: 

 

	 	(a)	if required by applicable law, rule, regulation, government requirement and/or court order, provided, that, the disclosing Party promptly notifies the
other Party of its notice of any such requirement and provides the other Party a reasonable opportunity to seek a protective order or other appropriate remedy and/or to waive compliance with the provisions of this Agreement;

  

	 	(b)	to the extent such use and disclosure occurs in the filing or publication of any patent application or patent on inventions, or to the extent such use and disclosure is
consented to pursuant to Section 8.7; 

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 38	  

					
	

	 		  	Execution Version

  

	 	(c)	as necessary or desirable for securing any regulatory approvals, including pricing approvals, for any Licensed Products, provided, that, the disclosing
Party shall take all reasonable steps to limit disclosure of the Confidential Information outside such regulatory agency and to otherwise maintain the confidentiality of the Confidential Information; 

 

	 	(d)	to take any lawful action that it deems necessary to protect its interest under, or to enforce compliance with the terms and conditions of, this Agreement; and

  

	 	(e)	to the extent necessary, to its Affiliates, directors, officers, employees, consultants, sublicensees, distributors, vendors and clinicians under written agreements of
confidentiality at least as restrictive on those set forth in this Agreement, who have a need to know such information in connection with such Party performing its obligations or exercising its rights under this Agreement. 

13.3 Certain Obligations. During the term of this Agreement and for a period of five (5) years thereafter and subject to the
exceptions set forth in Section 13.2, GenMark, with respect to ALL Confidential Information, and ALL, with respect to GenMark Confidential Information, agree: 

 

	 	(a)	to use such Confidential Information only for the purposes contemplated under this Agreement, 

 

	 	(b)	to treat such Confidential Information as it would its own proprietary information which in no event shall be less than a reasonable standard of care,

  

	 	(c)	to take reasonable precautions to prevent the disclosure of such Confidential Information to a Third Party without written consent of the other Party, and

  

	 	(d)	to only disclose such Confidential Information to those Affiliates, employees, agents and Third Party contractors, sublicensees and distributors who have a need to know
such Confidential Information for the purposes set forth herein and who are subject to obligations of confidentiality no less restrictive than those set forth herein. 

13.4 Disclosures and Public Announcements. Neither Party shall issue any press release or other publicity materials, or make any
public presentation with respect to the existence of, or any of the terms or conditions of, this Agreement without the prior written consent of the other Party. This restriction shall not apply to: 

 

	 	(a)	disclosures to a Party’s attorneys, advisors or investors on a need to know basis under circumstances that reasonably ensure the confidentiality thereof, and

  

	 	(b)	any future disclosures required by law or regulation, including as may be required in connection with any filings made with, or by the disclosure policies of a major
stock exchange, provided that the disclosing Party (i) use all reasonable efforts to inform the other Party prior to making any such disclosures and cooperate with 

  

					
	Development Collaboration and License Agreement	  	 	Page 39	  

					
	

	 		  	Execution Version

  

	 	the other Party in seeking a protective order or other appropriate remedy (including redaction) and (ii) whenever possible, request confidential treatment of such
information. 

 13.5 Scientific Publications. In the event that either Party wishes to publish or orally
present information arising from the Development Plan, such Party shall submit to the other Party all materials related to the proposed publication or presentation (including posters, abstracts, manuscripts and written descriptions of oral
presentations) at least thirty (30) days (or seven (7) days, in the case of abstracts) prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The reviewing
Party shall review such submitted materials and respond to the requesting Party as soon as reasonably possible, but in any case within ten (10) days (or three (3) Business Days, in the case of abstracts) of receipt thereof. At the request
of the reviewing Party, the requesting Party shall (i) modify or delete from such proposed publication or presentation any Confidential Information of the reviewing Party; and/or (ii) delay such proposed publication or presentation to
permit the preparation and filing of a patent application. For clarity, subject to the other provisions of this Article 13, except with respect to information arising from the Development Plan, the provisions of this Section 13.5
shall not apply to publications or presentations by GenMark, including with respect to information arising from GenMark’s development and commercialization activities under this Agreement. 

13.6 Consent to Disclose Redacted Agreement. GenMark consents to ALL’s disclosure of a redacted version of this Agreement to
*** , and CEA in a form approved by GenMark, such approval not to be unreasonably withheld. 
 ARTICLE 14: ARBITRATION

 14.1 Disputes. Except as otherwise expressly provided in this Agreement, any controversy, claim or legal
proceeding arising out of or relating to this Agreement, or the breach, termination or invalidity thereof (except for disagreements solely about decisions for which one Party has final decision making authority under this Agreements)
(“Dispute”) shall be first referred to the respective Chief Executive officers of each Party for resolution, prior to proceeding under the other provisions of Article 14. A Dispute shall be referred to such executives upon one Party
providing the other Party with notice that such Dispute exists, and such executives (or their designees) shall attempt to resolve such Dispute through good faith discussions. In the event that such Dispute is not resolved within thirty
(30) days of such other Party’s receipt of such notice, subject to Section 14.3, either Party may initiate the Dispute resolution provisions in Section 14.2. The Parties agree that any discussions between such
executives (or their designees) regarding such Dispute do not constitute settlement discussions, unless the Parties agree otherwise in writing. 
 14.2 Arbitration. Subject to Sections 14.1 and 14.3, the Parties agree to resolve any Dispute exclusively through binding arbitration conducted under the auspices of the American Arbitration
Association (the “AAA”) pursuant to AAA’s Commercial Arbitration Rules presently in effect. The arbitration shall be conducted in the English language before three (3) arbitrators appointed in accordance with the
Commercial Arbitration Rules presently in effect; 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 40	  

					
	

	 		  	Execution Version

  

 provided that at least one such arbitrator shall have had, by the time of the actual arbitration, at
least ten (10) years of experience as an attorney and experience in the medical diagnostics industry so as to better understand the legal, business and scientific issues addressed in the arbitration. Unless otherwise mutually agreed by the
Parties, any arbitration hereunder it shall be brought at the location of the Party which first received the notice required under Section 14.1. Unless agreed otherwise by the Parties, the Parties shall have thirty (30) days from
the appointment of the last to be appointed of the three (3) arbitrators to present and/or submit their positions to the arbitrators, and the Parties shall have a hearing before the arbitrators within ten (10) Business Days of such
submission. Each Party agrees to use reasonable efforts to make all of its current employees available, if reasonably needed, and agrees that the arbitrators may deem any party as “necessary.” The arbitrators shall hear evidence by each
Party and resolve each of the issues identified by the Parties. The arbitrators shall be instructed and required to render a written, binding, non-appealable resolution and award on each issue which clearly states the basis upon which such
resolution and award is made. The written resolution and award shall be delivered to the Parties as expeditiously as possible, but in no event more than thirty (30) days after conclusion of the hearing, unless otherwise agreed to by the
Parties. The Parties shall use all reasonable efforts to keep arbitration costs to a minimum. Each Party must bear its own attorneys’ fees and associated costs and expenses. Each Party agrees that, notwithstanding any provision of applicable
law or of this Agreement, it will not request, and the arbitrators shall have no authority to award, punitive or exemplary damages against any Party. 
 14.3 Subject Matter Exclusions. Notwithstanding the foregoing, the provisions of Sections 14.1 and 14.2 shall not apply to any Dispute relating to: (i) the validity, infringement,
enforceability or claim interpretation relating to a Party’s patents, trademarks or copyright, which, for Patents that is issued in the United States, be subject to actions before the United States Patent and Trademark Office and/or submitted
exclusively to the federal court located in the jurisdiction of the district where any of the defendants reside; or (ii) any antitrust, anti- monopoly or competition law or regulation, whether or not statutory. 

14.4 Equitable Relief. Nothing in this Agreement shall be deemed as preventing the Parties from seeking injunctive relief (or
other provisional remedy) from any court having jurisdiction over the Parties and the subject matter of the dispute as necessary to protect either Party’s interests. 
 ARTICLE 15: MISCELLANEOUS 
 15.1 Government Rights. This Agreement
is subject to Title 35 Sections 200-204 of the United States Code. Among other things, these provisions provide the United States Government with nonexclusive rights in certain of the ALL IP Rights. 

15.2 Assignment and Delegation. Neither this Agreement nor any right or obligation hereunder shall be assignable in whole or in
part, whether by operation of law, or otherwise by either Party without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may assign or transfer its rights and obligations under this Agreement to a Person that
succeeds to all or substantially all of that Party’s business or assets whether by sale, merger, operation of law or otherwise. In addition, either Party may assign all or part of this agreement

  

					
	Development Collaboration and License Agreement	  	 	Page 41	  

					
	

	 		  	Execution Version

  

 
to an Affiliate. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the Parties hereto and their respective successors and permitted assignees. Any transfer or
assignment of this Agreement in violation of this Section 15.1 shall be null and void. 
 15.3 Change in
Control. At least ninety (90) days in advance of any proposed Change in Control, ALL shall provide GenMark with written notice thereof. Within five (5) Business Days of any Change of Control, ALL shall provide GenMark with written
notice thereof. 
 15.4 Entire Agreement; Prior Agreements. This Agreement contains the entire agreement between the
Parties relating to the subject matter hereof, and all prior understandings, representations and warranties between the Parties are superseded by this Agreement. The Heads of Agreement dated March 30, 2012, and the Letter Agreement dated
April 25, 2012 (the “Letter Agreement”), between the Parties are hereby terminated in their entireties. All Statements of Work entered into by the Parties pursuant to the Letter Agreement are hereby incorporated into this Agreement as
part of the Development Plan, and any and all inventions and know-how (whether or not patentable) that were first invented (as that term is defined under U.S. Patent Laws) as a direct result of activities undertaken under the Letter Agreement,
including activities performed by a third party on a party’s behalf, shall be Collaboration Inventions under this Agreement and subject to all terms and conditions of this Agreement applicable thereto. As of the Effective Date, this Agreement
supersedes the Mutual Confidentiality Agreement between the parties and effective June 30, 2010 (“Mutual CDA”), but only insofar as it relates to the subject matter of this Agreement. All “Proprietary Information” (as
defined in the Mutual CDA) exchanged between the Parties thereunder following the Effective Date relating to the subject matter of this Agreement shall be deemed Confidential Information hereunder and shall be subject to the provisions of this
Article 13. 
 15.5 Amendments. Changes and additional provisions to this Agreement shall be binding on the
Parties only if mutually agreed upon, laid down in writing and signed effectively by the Parties. 
 15.6 Applicable Law.
This Agreement shall be construed and interpreted in accordance with the laws of California and all rights and remedies shall be governed by such laws without regard to principles of conflicts of law. 

15.7 Force Maieure. If the performance of this Agreement or any obligations hereunder is prevented, restricted or interfered with
by reason of earthquake, fire, flood or other casualty, or due to strikes, riot, storms, explosions, acts of God, war, or a similar occurrence or condition beyond the reasonable control of the Parties, the Party so affected shall, upon giving prompt
notice to the other Parties, be excused from such performance during such prevention, restriction or interference, and any failure or delay resulting therefrom shall not be considered a breach of this Agreement. 

15.8 Severability. The Parties do not intend to violate any public policy or statutory common law. However, if any sentence,
paragraph, clause or combination of this Agreement is in violation of any law or is found to be otherwise unenforceable, such sentence, paragraph, clause or combination of the same shall be deleted and the remainder of this Agreement shall remain
binding, provided that such deletion does not alter the basic purpose and structure of this Agreement. 

  

					
	Development Collaboration and License Agreement	  	 	Page 42	  

					
	

	 		  	Execution Version

  

 15.9 Notices. All notices, requests, demands, and other communications relating
to this Agreement shall be in writing in the English language and shall be delivered in person or by mail, international courier or facsimile transmission (with a confirmation copy forwarded by courier or mail). Notices sent by mail shall be sent by
first class mail or the equivalent, registered or certified, postage prepaid, and shall be deemed to have been given on the date actually received. Notices sent by international courier shall be sent using a service which provides traceability of
packages. Notices shall be sent as follows: 
  

			
	 Notices to GenMark:
  

GenMark Diagnostics, Inc.
 5964 La Place
Court
 Carlsbad, CA 92008
 Attention:
Corporate Secretary
 Telephone: (760) 448-4300
 Facsimile: (760) 448-4301
  

Notices to the ALL:
  
 For delivery via U.S. Postal Service:
  
 Advanced Liquid Logic, Inc.
 PO Box 14025
 Research Triangle Park, NC 27709
 Attention: Chief Executive Officer

Telephone: (919) 287-9010
 Facsimile: (919)
287-9011
	  	 with a copy to:
  

GenMark Diagnostics, Inc.
 5964 La Place
Court
 Carlsbad, CA 92008
 Attention:
SVP, Research and
 Development

Telephone: (760) 448-4300
 Facsimile: (760)
448-4301
  
 with a copy to:

 
 For delivery via courier:

 
 Advanced Liquid Logic, Inc.
 615 Davis Drive, Suite 800
 Morrisville NC, 27560

Attention: Chief Executive Officer
 Telephone:
919) 287-9010
 Facsimile: (919) 287-9011

 Either Party may change its address for notices or facsimile number at any time by sending written notice
to the other Party pursuant to this Section 15.9. 
 15.10 Independent Contractor. Nothing herein shall
create any association, partnership, joint venture, fiduciary duty or the relation of principal and agent between the Parties hereto, it being understood that each Party is acting as an independent contractor, and neither Party shall have the
authority to bind the other or the other’s representatives in any way. 
 15.11 Waiver. No delay on the part of
either Party hereto in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any power or right hereunder preclude other or further exercise thereof or the exercise of any other power
or right. No waiver of this Agreement or any provision hereof shall be enforceable against any Party hereto unless in writing, signed by the Party against whom such waiver is claimed, and shall be limited solely to the one event. 

  

					
	Development Collaboration and License Agreement	  	 	Page 43	  

					
	

	 		  	Execution Version

  

 15.12 Interpretation. This Agreement has been prepared jointly and no rule of
strict construction shall be applied against either Party. In this Agreement, the singular shall include the plural and vice versa and the word “including” shall be deemed to be followed by the phrase “without limitation.” The
section headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement. 
 15.13 Counterparts. This Agreement may be executed in counterparts, each of which together shall constitute one and the same Agreement. For purposes of executing this agreement, a facsimile copy of
this Agreement, including the signature pages, will be deemed an original. 
 15.14 License Survival During Bankruptcy.
All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Paragraph 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under
Paragraph 101(35A) of the U.S. Bankruptcy Code. The Parties agree that GenMark and ALL, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their respective rights and elections under the U.S. Bankruptcy
Code. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against ALL, including under the U.S. Bankruptcy Code, GenMark shall be entitled to a complete duplicate of (or complete access to, as
appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in GenMark’s possession, shall be promptly delivered to GenMark upon any such commencement of a bankruptcy proceeding
upon written request therefore by GenMark. 
 15.15 Export Regulations. Licensed Products may be subject to Applicable
Laws governing export of goods and information, including the U.S. Export Administration Act and its associated regulations, and may be subject to Applicable Laws governing export or import in other countries. GenMark agrees to comply with such
Applicable Laws and acknowledges that it has the responsibility to obtain all necessary licenses to export, re-export, or import Licensed Products. 
 15.16 Non-Solicitation. During the Term and for one (1) year thereafter, neither Party shall directly and actively induce or attempt to induce any current employee of the other Party or any of
its Affiliates, to accept employment with the other Party or any of its Affiliates. The foregoing will not apply to individuals hired as a result of the use of an independent employment agency (so long as the agency was not directed to solicit a
particular individual) or as a result of the use of a general solicitation (such as internet-based, newspaper advertisement or on radio or television) not specifically directed to employees of the other party. 

15.17 Names. GenMark shall not use any name, trade name, trademark or other designation of the *** or its employees (including
contraction, abbreviation or simulation of any of the foregoing) in advertising, publicity or other promotional activity. Unless required by Applicable Law, GenMark shall not use the name “***” or the name of any *** in advertising,
publicity or other promotional activity without written permission of the ***. 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Page 44	  

					
	

	 		  	Execution Version

  

 IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized
representative. 
  

									
	Advanced Liquid Logic, Inc.	 		 	GenMark Diagnostics, Inc.
					
	By:	 	 /s/ Richard M. West
	 		 	By:	 	 /s/ Hany Massarany

					
	Name:	 	 Richard M. West
	 		 	Name:	 	 Hany Massarany

					
	Title:	 	 Chief Executive Officer
	 		 	Title:	 	 CEO

					
	Date:	 	 July 26, 2012
	 		 	Date:	 	 July 25, 2012

  

					
	Development Collaboration and License Agreement	  	 	Page 45	  

					
	

	 		  	Execution Version

  

 Schedule A 

Development Plan 

  

					
	Development Collaboration and License Agreement	  	 	Schedule A	  

					
	

	 		  	CONFIDENTIAL

  

 DEVELOPMENT PLAN 

*** 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

			
	Page 1 of 9	  	

					
	

	 		  	CONFIDENTIAL

  

 *** 
 ***END OF DOCUMENT*** 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  
 Page 9 of 9

					
	

	 		  	Execution Version

  

 Schedule B 

Stock Purchase Agreement 
 *** 
  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. 

  

					
	Development Collaboration and License Agreement	  	 	Schedule B

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]